---
title: "Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Clinical evidence"
description: "Formulary evidence on Duravyu (vorolanib intravitreal insert, EYP-1901) in Wet age-related macular degeneration: Clinical evidence. Covers LUGANO, LUCIA, DAVIO 2, DAVIO, APEX, and X82-OPH-102. 249 evidence topics quoted from 54 sources."
canonical: "https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/clinical-evidence"
published: "2026-09-17T18:16:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 LUGANO

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Registered study summary

> “This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.”

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-3.1.1.1-2"></a>

###### Program objective: similar vision with dosing every 6 months and lower treatment burden

> “Objective of the Phase 3 wet AMD program is to demonstrate DURAVYU, when administered every six months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

> “LUGANO (NCT06668064) and LUCIA (NCT06683742) aim to demonstrate that EYP-1901, when administered every 6 months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden in patients with wet AMD”

Source: [Patel and Ribeiro (2025)](https://eyepointpharma.com/wp-content/uploads/2025/05/ARVO-2025_LUGANO-LUCIA_Patel_FINAL.pdf)

<a id="topic-3.1.1.1-3"></a>

###### Role in the planned New Drug Application

> “If the wet AMD Phase 3 clinical program is successful, we plan on filing a New Drug Application (NDA) with the U.S Food and Drug Administration (FDA) with the initial 56-week efficacy and safety data. A supplemental NDA (sNDA) is planned for the Year 2 safety data only, once complete.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Summary: sites and timeline

The ClinicalTrials.gov record (last updated 2026-09-03) lists 76 locations, all in the United States, which is consistent with the 2025 Form 10-K description of LUGANO as the United States trial and LUCIA as the United States and ex-United States trial; the first-participant announcement and a 2025 congress poster described both trials as global. The first participant was dosed in October 2024 (registry study start 2024-10-22), enrollment was completed on May 27, 2025, the registry reports actual primary completion on 2026-07-13, and topline results were announced on August 17, 2026. Estimated study completion (week 96) is 2027-08.

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064); [EyePoint Pharmaceuticals Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025034601/eypt-20241231.htm); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint Pharmaceuticals LUGANO first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-ex99_1.htm); [Patel and Ribeiro (2025)](https://eyepointpharma.com/wp-content/uploads/2025/05/ARVO-2025_LUGANO-LUCIA_Patel_FINAL.pdf)

<a id="topic-3.1.1.2-2"></a>

###### Registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2024-10-22” |
| Primary completion (actual) | “2026-07-13” |
| Study completion (estimated) | “2027-08” |

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-3.1.1.2-3"></a>

###### United States trial

> “The LUGANO (US) trial remains on track to randomize patients for inclusion in 2024 with LUCIA (US/ex-US) to follow.”

Source: [EyePoint Pharmaceuticals Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025034601/eypt-20241231.htm)

<a id="topic-3.1.1.2-4"></a>

###### First participant dosed

> “today announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU”
> “With over 150 clinical trial sites already committed, we believe we are well positioned to rapidly enroll patients globally in the pivotal LUGANO trial, with the LUCIA trial to quickly follow”

Source: [EyePoint Pharmaceuticals LUGANO first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-ex99_1.htm)

<a id="topic-3.1.1.2-5"></a>

###### Enrollment completion

> “We successfully completed enrollment in our two pivotal Phase 3 clinical trials: the LUGANO trial on May 27, 2025, and the LUCIA trial on July 29, 2025.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “The seven-month enrollment for LUGANO represents one of the fastest enrolling Phase 3 pivotal trials for wet AMD to date.”

Source: [EyePoint Pharmaceuticals LUGANO enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/eypt-ex99_1.htm)

<a id="topic-3.1.1.2-6"></a>

###### Topline results announcement

> “WATERTOWN, Mass., August 17, 2026 (GLOBE NEWSWIRE)”
> “today announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Phase 3, randomized, double-masked, parallel-group, aflibercept-controlled design

> “A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD”

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-3.1.1.3-2"></a>

###### Two identical non-inferiority trials with randomization on Day 1

> “LUGANO and LUCIA are identical, randomized, double-masked, aflibercept controlled, non-inferiority Phase 3 trials assessing the efficacy and safety of DURAVYU in patients with active wet AMD including both treatment naïve and treatment experienced patients.”
> “At Day 1, patients are randomized 1:1 to receive either DURAVYU 2.7mg every six months or on-label aflibercept as control.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-3.1.1.3-3"></a>

###### Design elements agreed with FDA and EMA

> “In June 2024, we announced alignment on pathway to approval with U.S. Food and Drug Administration (FDA) based on positive End of Phase 2 meeting in April 2024 for two non-inferiority trials, 6-month redosing of DURAVYU™ and sham for masking with a one-year endpoint.”
> “Safety evaluation only will be continued through year two of the trials.”

Source: [EyePoint Pharmaceuticals Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025034601/eypt-20241231.htm)

> “The Phase 3 program was developed with feedback from both the FDA and European Medicines Agency (EMA).”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-3.1.1.3-4"></a>

###### Aflibercept loading, sham masking, and 24-month safety follow-up

> “All participants will receive 3 loading doses of aflibercept”
> “Sham injections will be used for masking”
> “Primary efficacy endpoint at 12 months”
> “Safety monitored for 24 months”

Source: [Patel and Ribeiro (2025)](https://eyepointpharma.com/wp-content/uploads/2025/05/ARVO-2025_LUGANO-LUCIA_Patel_FINAL.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Monthly monitoring with supplemental treatment in all arms

> “Patient-centric design – monthly disease monitoring, including imaging”
> “All patients receive active treatment, and supplemental treatment per criteria, to ensure disease control”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

<a id="topic-3.1.1.3-6"></a>

###### Independent Data Safety Monitoring Committee

> “The DSMC is an independent panel of experts in ophthalmology and biostatistics who are responsible for reviewing safety data to ensure the welfare of trial participants and to provide recommendations regarding trial conduct.”
> “DSMC meetings are scheduled to occur every six months per the trial protocol, and this is the last anticipated DSMC meeting ahead of topline data.”

Source: [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Minimum age | “50 Years” |
| Diagnosis and prior treatment status | “Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.” |
| Visual acuity in the study eye | “Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).” |
| Previously treated participants | “For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.” |

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-3.1.1.4-2"></a>

###### Key exclusion criteria

> “Subfoveal fibrosis, atrophy, or scarring in the center subfield”
> “Fellow eye BCVA <20 ETDRS letters (20/400 Snellen equivalent)”

Source: [Patel and Ribeiro (2025)](https://eyepointpharma.com/wp-content/uploads/2025/05/ARVO-2025_LUGANO-LUCIA_Patel_FINAL.pdf)

<a id="topic-3.1.1.4-3"></a>

###### Geographic atrophy outside the center subfield was not excluded

> “Note: These patients met criteria for enrollment, as exclusion criteria regarding GA involved presence of atrophy in the center subfield at baseline.”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.4-4"></a>

###### Planned mix of treatment-naive and previously treated participants

> “Trials include approximately 75% treatment-naïve and 25% previously treated patients.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Registered arms

| Arm | Arm label | Intervention |
| --- | --- | --- |
| Experimental | “EYP-1901 2686 µg” | “Intravitreal Injection” |
| Active comparator | “Aflibercept” | “Aflibercept (2.0 mg)” |

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-3.1.1.5-2"></a>

###### Dosing schedule: vorolanib insert every 6 months from week 8

> “Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial with a total of four injections over the two-year trial.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “DURAVYU dosing consists of 2 inserts delivered in a single injection.”
> “Primary endpoint Blend W52 & W56 DURAVYU 2.7 mg q6M Aflibercept 2 mg q8W”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.5-3"></a>

###### Aflibercept loading doses before the first insert

> “Patients will receive DURAVYU every six months or on-label aflibercept every two months, beginning after three loading doses of aflibercept with randomization occurring on Day 1.”

Source: [EyePoint Pharmaceuticals LUGANO first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024116847/eypt-ex99_1.htm)

> “In the phase 3 wet AMD studies, patients are randomized either to receive 2.7 mg EYP-1901 after 3 loading doses of aflibercept or to receive aflibercept every other month after loading. Patients are followed monthly over 2 years and can receive supplemental treatment according to prespecified retreatment criteria.”

Source: [Abbey (2026)](https://www.retinalphysician.com/issues/2026/retina-world-congress/eyp1901-program-overview)

<a id="topic-3.1.1.5-4"></a>

###### Dosing visits reached during the trial

> “all patients across the LUGANO and LUCIA trials reached the Week 8 visit during which patients in the DURAVYU arms received their initial DURAVYU dose”

Source: [EyePoint Pharmaceuticals DSMC recommendation announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/d65451dex991.htm)

> “As of May 2, 2026, all active patients in the treatment arm have reached the Week 32 visit, during which patients received their second DURAVYU dose. Over 35% of those patients have also received their third planned dose at Week 56.”

Source: [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)

<a id="topic-3.1.1.5-5"></a>

###### Supplemental aflibercept criteria: 2026 presentation

> “> 5 letter drop with 75 microns new fluid from AMD compared to best on study, or new, sight threatening hemorrhage due to wet AMD”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.5-6"></a>

###### Supplemental aflibercept criteria: 2025 congress presentation

> “Supplemental aflibercept per prespecified criteria (all arms)”
> “BCVA reduction of ≥5 letters from best on-study measurement due to nAMD AND CST increase of ≥75 microns on SD-OCT from lowest on-study measurement”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Mean Change in Best Corrected Visual Acuity as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered outcomes

| Outcome type | Measure | Time frame |
| --- | --- | --- |
| Primary | “Average change in best corrected visual acuity (BCVA)” | “Weeks 52 and 56” |
| Secondary | “Rate of injection burden” | “Week 56” |
| Secondary | “Average change in best corrected visual acuity (BCVA)” | “Week 96” |

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint and non-inferiority margin of 4.5 letters

> “Primary Endpoint: Non-inferior (NI) mean change in BCVA from Day 1 to Week 52 and Week 56 (blended) vs aflibercept control (NI margin of -4.5 letters)”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.6.1-3"></a>

###### Secondary endpoints

> “The primary endpoint is the difference in mean change in best corrected visual acuity (BCVA) from Day 1 to Week 52 and 56 (blended) versus aflibercept control. Secondary endpoints include safety, reduction in treatment burden, percentage of eyes free of supplemental aflibercept injections, and anatomical stability.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “Key Secondary Endpoints: Safety Reduction in treatment burden (superiority vs on-label aflibercept) Percent of eyes supplement-free Anatomic stability”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.6.1-4"></a>

###### Company rationale: established regulatory precedent

> “CLINICALLY RELEVANT TRIAL DESIGN NI margin precedent for regulatory approval”
> “Follows non-inferiority pathway of five most recent FDA approvals in wet AMD”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.6.1-5"></a>

###### Precedent: 4.5-letter margin in the Archway port delivery system trial

> “Primary end point was change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter (letters) score from baseline averaged over weeks 36 and 40 (noninferiority margin,-4.5 letters; equivalence margin, ±4.5 letters).”

Source: [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)

<a id="topic-3.1.1.6.1-6"></a>

###### Precedent: 4.5-letter margin described as based on FDA guidance for another sustained-release tyrosine kinase inhibitor

> “Based on FDA guidance, the non-inferiority margin for the lower bound for the trial has been established at -4.5 letters of mean BCVA.”

Source: [Ocular Therapeutix Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm)

<a id="topic-3.1.1.6.1-7"></a>

###### Precedent: 4-letter margins in phase 3 trials versus aflibercept 2 mg every 8 weeks

> “The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

> “The least squares mean differences between aflibercept 8q12 versus 2q8 and 8q16 versus 2q8, respectively, were -0·97 (95% CI -2·87 to 0·92) and -1·14 (-2·97 to 0·69) letters (non-inferiority margin at 4 letters).”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="topic-3.1.1.6.1-8"></a>

###### FDA framework for selecting a non-inferiority margin

> “M1 = the entire effect of the active control assumed to be present in the NI study”
> “M2 = the largest clinically acceptable difference (degree of inferiority) of the test drug compared to the active control”
> “The choice of M2 is a matter of clinical judgment, but M2 can never be greater than M1”

Source: [FDA Non-Inferiority Clinical Trials to Establish Effectiveness guidance (2016)](https://www.fda.gov/media/78504/download)

<a id="topic-3.1.1.6.1-9"></a>

###### Treatment burden endpoint: injection count definition

> “For DURAVYU group: the number of injections includes the DURAVYU injections at Week 8 and Week 32, and all supplemental injections after Week 8 through Week 56. For aflibercept group: the number of injections includes all aflibercept and supplemental injections after Week 8 through Week 56. Scheduled aflibercept injections from Day 1 through Week 8 were excluded. Week 56 study treatment injection was excluded from this analysis.”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.6.1-10"></a>

###### Archway: justification for the 4.5-letter noninferiority and equivalence margins

> “The noninferiority and equivalence margins were chosen to reduce the possibility of a positive trial where the lower confidence level was too close to the current consensus definition of a clinically meaningful difference of 5 letters.”

Source: [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/)

<a id="topic-3.1.1.6.1-11"></a>

###### TENAYA and LUCERNE: sample size, endpoint averaging, and choice of the every-8-week aflibercept comparator

> “Sample size of approximately 320 patients in each treatment group (ie, N=640 per trial) was estimated to provide more than 90% power to test the primary comparison of non-inferiority of faricimab (up to every 16 weeks) to aflibercept (every 8 weeks) for each trial, using a non-inferiority margin of four ETDRS letters”
> “Primary efficacy outcome was averaged over three timepoints to limit impact of measurement variability and account for differences in time from last dose received by patients across treatment groups on different dosing intervals.”
> “Lower bounds of the two-sided 95% CIs for difference in adjusted means of the two treatments were well within the non-inferiority margin of four letters, establishing non-inferiority of faricimab to aflibercept”
> “Fixed 8-week aflibercept dosing, which was used in the pivotal phase 3 trials of aflibercept, was therefore the most appropriate regimen against which to evaluate noninferiority of a new treatment, especially considering the potential for extended dosing with faricimab at up to 16-week repeating intervals.”

Source: [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/)

Additional sources: [Csaky et al. (2008)](https://doi.org/10.1167/iovs.07-1132)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment

| Source field | Value |
| --- | --- |
| Registry enrollment (estimated) | “400” |

Source: [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064)

> “Each trial is expected to enroll approximately 400 patients who will be randomly assigned 1:1 to a 2.7mg dose of DURAVYU™ or an on-label aflibercept control.”

Source: [EyePoint Pharmaceuticals Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025034601/eypt-20241231.htm)

<a id="topic-3.1.1.7.1-2"></a>

###### Enrolled and randomized participants

> “The LUGANO trial enrolled 432 patients and the LUCIA trial enrolled 475 patients who were randomly assigned, 1:1, to a DURAVYU 2.7mg arm or an on-label aflibercept control arm.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants analyzed

| Analysis | DURAVYU 2.7 mg | Aflibercept 2 mg |
| --- | --- | --- |
| Baseline characteristics and efficacy | “DURAVYU 2.7mg (n=211)” | “Aflibercept 2mg q8W (n=216)” |
| Ocular adverse events | “DURAVYU 2.7mg (N=211)” | “Aflibercept 2mg (N=221)” |

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.7.1-4"></a>

###### Sample size calculation and power

No evidence found.

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Summary: analysis methods and populations reported

The topline presentations report the primary endpoint as a mixed model for repeated measures (MMRM) estimate of change from baseline blended across weeks 52 and 56, tested against a margin of -4.5 letters. Efficacy tables use 211 participants in the vorolanib insert arm and 216 in the aflibercept arm (427 of 432 randomized participants, 98.8%); the ocular adverse event table uses 211 and 221 participants (432 of 432). The definition of the efficacy population, the method for handling missing data, the confidence interval for the full-dataset treatment difference, and any multiplicity procedure for secondary endpoints were not reported. All p-values for the ad hoc analysis, the prespecified supplement-free subgroup analysis, and the treatment burden endpoint were labeled nominal. The September 2026 presentation added a median regression analysis and a randomization simulation labeled as new analyses. All results were labeled preliminary and pending final analysis.

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-3.1.1.7.2-2"></a>

###### Primary analysis model

> “Blended week 52 and week 56 change vs. baseline by MMRM”
> “Preliminary data – pending final analysis”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.7.2-3"></a>

###### Ad hoc analysis excluding the asymmetric cohort

> “DURAVYU was non-inferior to on-label aflibercept (nominal p-value = 0.0096) in an”
> “analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “Note: Main cause of vision loss was determined by multiple retina specialists reviewing study and reading center data (including OCT, FA/CFP, and FAF imaging).”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.7.2-4"></a>

###### Prespecified supplement-free subgroup analysis

> “Pre-specified analysis of change in BCVA from baseline to average Week 52/56 in supplement-free patients showed that DURAVYU was non-inferior (nominal p-value=0.0035) versus on-label aflibercept”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-3.1.1.7.2-5"></a>

###### Median regression sensitivity analysis

> “Median Regression is more robust than MMRM/ANCOVA to extremes”
> “Analysis performed on all patients with available Week 52 or Week 56 BCVA.”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.7.2-6"></a>

###### Treatment burden analysis population

> “Participants who discontinued treatment or study early without any Week 8 or later injections of study drug were not included.”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.7.2-7"></a>

###### Multiplicity control and handling of missing data

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Summary: disposition through week 56

Of 432 randomized participants, 211 in the vorolanib insert arm and 216 in the aflibercept arm were included in efficacy analyses, and 211 and 221 in the ocular adverse event table. Discontinuation through week 56 was 6% in each arm, and none was attributed to the vorolanib insert. Reading center assessments at week 56 included 193 and 197 participants for subretinal fibrosis and 168 per arm for fundus autofluorescence. A full CONSORT flow was not reported.

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.1-2"></a>

###### Discontinuations through week 56

> “Low patient discontinuation rate of 6% through Week 56 in each arm”
> “No study or treatment discontinuations were related to DURAVYU”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.1-3"></a>

###### Participants with reading center assessments at week 56

> “Week 56 4.1% (8 of 193) 4.1% (8 of 197)”
> “Geographic Atrophy Present by FAF Baseline (n=180 per arm) Week 56 (n=168 per arm)”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographics, treatment history, and ocular characteristics

| Characteristic | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg q8W (n=216) |
| --- | --- | --- |
| Age, years, mean (SD) | “77.5 (7.52)” | “77.0 (7.61)” |
| Age 65 years or older, n (%) | “202 (95.7)” | “205 (94.9)” |
| Female, n (%) | “136 (64.5)” | “141 (65.3)” |
| Treatment naive, n (%) | “159 (75.4)” | “164 (75.9)” |
| Previously treated, n (%) | “52 (24.6)” | “52 (24.1)” |
| Annualized number of anti-VEGF injections for previously treated, mean (SD) | “7.35 (2.21)” | “7.39 (2.01)” |
| BCVA, ETDRS letters, mean (SD) | “65.8 (8.95)” | “64.3 (10.35)” |
| Better than 20/40 Snellen equivalent, n (%) | “82 (38.9)” | “79 (36.6)” |
| 20/40 Snellen equivalent or worse, n (%) | “129 (61.1)” | “137 (63.4)” |
| Central subfield thickness, µm, mean (SD) | “319.83 (71.429)” | “326.01 (71.906)” |
| Total CNV area by fluorescein angiography, mm2, mean (SD) | “5.69 (4.44)” | “4.60 (3.86)” |
| Medical history of dry AMD in study eye | “24.6%” | “21.7%” |
| Medical history of glaucoma in study eye | “11.4%” | “5.9%” |

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.2-2"></a>

###### Geographic atrophy at baseline

> “DURAVYU Treated Eyes (n=211) Untreated Fellow Eye (n=211) Number of eyes w GA at the start of the study n=14 n=25”
> “In DURAVYU eyes, GA started meaningfully closer to fovea at baseline compared to control, therefore at higher risk of losing vision”
> “Distance from fovea DURAVYU 2.7mg (N=14) Aflibercept 2mg (N=17) At baseline 825 microns 1009 microns Change from Baseline -236 microns -254 microns”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Summary: primary and key secondary efficacy results

LUGANO did not meet its primary endpoint of non-inferiority (margin -4.5 letters) in mean BCVA change from baseline to weeks 52 and 56 in the full dataset; the numeric treatment difference and confidence interval for the full dataset were not reported in text. In the full dataset, the vorolanib insert arm showed a mean BCVA gain from baseline. Nine of 211 participants (4.3%) in the vorolanib insert arm and none of 216 in the aflibercept arm lost 15 or more letters from causes the company attributed to conditions other than wet AMD (geographic atrophy, 6; glaucoma, 2; retinal detachment, 1). In an ad hoc analysis excluding these 9 participants, least squares mean BCVA change was +3.5 letters with the vorolanib insert and +5.9 letters with aflibercept (difference -2.4 letters; nominal p=0.0096). In the September 2026 presentation, a median regression analysis of all participants with week 52 or week 56 BCVA gave a median difference of -1.4 letters, and random reassignment of the 16 participants with any loss of 15 or more letters gave modeled differences of -1.3 to -2.0 letters. The presentation chart shows 15-letter or greater loss in 7.5% of the vorolanib insert arm (4.5% attributed to non-wet AMD causes) and 0.5% of the aflibercept arm.

Mean injections after loading through week 56 were 3.1 with the vorolanib insert and 5.3 with aflibercept, a 42% reduction (nominal p<0.0001), with an average of 1.1 supplemental injections annualized in the vorolanib insert arm. Supplement-free rates in the vorolanib insert arm were 76% through week 32 and 54% through week 56. In the supplement-free subgroup (113 participants receiving the vorolanib insert, compared with 192 aflibercept participants shown in the chart legend), BCVA change was +4.7 versus +6.4 letters (difference -1.8; nominal p=0.0035). Mean central subfield thickness change at week 56 was -72 µm versus -76 µm (difference +4 µm).

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary endpoint: full dataset

> “the primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset, confounded by this asymmetric cohort.”
> “In contrast, no patients experienced vision loss (≥ 15 letters) unrelated to wet AMD in the aflibercept control arm.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “DURAVYU did not achieve statistical non-inferiority in full data set”
> “DURAVYU resulted in visual gains, on average”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.3-3"></a>

###### Primary endpoint: full-dataset treatment difference and confidence interval

No evidence found.

<a id="topic-3.1.1.8.3-4"></a>

###### Asymmetric cohort with vision loss attributed to causes other than wet AMD

> “9 patients lost ≥15 letters of vision due to non-wAMD etiologies Geographic atrophy (n=6) Glaucoma (n=2) Retinal detachment (n=1) All 9 had good anatomic control of their wet AMD 6 of 9 received supplemental injections – none improved VA 258 total letters lost by this cohort”
> “Zero patients (of 216) in aflibercept control arm”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

> “No eyes in the control arm had vision loss ≥15 letters due to non-AMD causes No imbalance in vision loss 10-14 letters”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.3-5"></a>

###### Ad hoc analysis excluding the asymmetric cohort

| Measure | Value |
| --- | --- |
| Least squares mean BCVA change, DURAVYU 2.7 mg, excluding asymmetric cohort | “DURAVYU arm gained +3.5 letters” |
| Least squares mean BCVA change, aflibercept 2 mg | “+5.9” |
| Mean change in BCVA versus aflibercept | “-2.4” |
| p-value | “(nominal non-inferiority p=0.0096)” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.3-6"></a>

###### Sensitivity analyses reported in September 2026

> “Median Change in BCVA vs. Aflibercept * -1.4”
> “Random reassignment of the 16 LUGANO patients with any ≥15-letter vision loss resulted in DURAVYU non-inferiority in every simulation”
> “Modeled BCVA outcome range: -1.3 to -2.0”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.3-7"></a>

###### Loss of 15 or more letters in the aflibercept arm compared with prior trials

| Trial | Aflibercept 2 mg every 8 weeks, N | Timepoint | Participants with loss of 15 or more letters |
| --- | --- | --- | --- |
| VIEW 1 | “301” | “Week 52” | “4.9%a” |
| VIEW 2 | “306” | “Week 52” | “4.4%a” |
| HAWK | “360” | “Week 48” | “5.5%b” |
| HARRIER | “369” | “Week 48” | “4.8%b” |
| TENAYA | “300” | “Week 40-48, avg” | “5.9%c” |
| LUCERNE | “291” | “Week 40-48, avg” | “2.7%d” |
| PULSAR | “335” | “Week 48” | “3.3%e” |
| DAVIO 2 | “54” | “Week 56” | “7.7%f” |
| LUGANO | “216” | “Week 52/56, avg” | “0.5%f” |

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.3-8"></a>

###### Treatment burden

> “42% reduction in treatment burden, achieving superiority versus on-label aflibercept (nominal p-value<0.0001) compared to a maximum possible reduction of 60%”
> “This reduction translates to two fewer injections on average in DURAVYU patients versus on-label aflibercept up to Week 56”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “Total Injections* After Loading Doses (Avg.)”
> “5.3 3.1 Treatment Burden Reduction achieving superiority to on-label aflibercept (maximum 60%) 42% Fewer Injections on average, in DURAVYU patients vs. on-label aflibercept 1.1 2 nominal p<0.0001”
> “1.1 average supplemental injection annualized”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.3-9"></a>

###### Supplement-free rates in the vorolanib insert arm

| Measure | Up to week 32 | Up to week 56 |
| --- | --- | --- |
| Supplement-free patients | “76% of DURAVYU patients were supplement-free up to Week 32” | “54% of DURAVYU patients were supplement-free up to Week 56” |
| Zero or one supplement | “94 % of DURAVYU patients received zero or one supplement up to Week 32” | “79% of DURAVYU patients received zero or one supplement up to Week 56” |

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “DURAVYU 2.7mg Up to Week 32 Up to Week 56 Supplement-Free Patients 76% 54% Patients with 0 or 1 Supplement 96% 79% Patients with 2 or fewer Supplements 99% 88%”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.3-10"></a>

###### Supplement-free subgroup: visual acuity and central subfield thickness

> “DURAVYU was Non-Inferior to On-Label Aflibercept Control In Supplement-Free Subgroup (n=113, 54%)”
> “Mean change in CST vs. Aflibercept +3 µm”
> “vs. Aflibercept -1.8”
> “This analysis includes 3 patients who experienced ≥15-letter vision loss not due to wet AMD. The mean change in BCVA would have been -1.1 excluding the 3.”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.3-11"></a>

###### Response to supplemental aflibercept

> “Visual Acuity Before and After Supplementation -6.4 letters +0.1 letters Aflibercept supplement did not maintain BCVA Aflibercept supplement maintained BCVA DURAVYU Patients Receiving Supplements, Excluding Asymmetric Cohort (n=92) Patients in Asymmetric Cohort Receiving Supplements (n=6)”
> “Note: 3/9 patients in asymmetric cohort did not receive supplement”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.3-12"></a>

###### Anatomic outcomes: central subfield thickness

> “Strong anatomic control demonstrated DURAVYU’s potency with a mean difference of 4 microns versus on-label aflibercept control in central subfield thickness (CST) at Week 56”
> “The 54% of DURAVYU eyes that were supplement free up to week 56 showed only a 3-micron difference in CST compared to the on-label aflibercept control”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “Mean Change in CST from Baseline Through Week 56 Week -76 µm -72 µm Mean change in CST vs. Aflibercept +4 µm”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.3-13"></a>

###### Anatomic outcomes: subretinal fibrosis

| Measure | DURAVYU 2.7 mg | Aflibercept 2 mg |
| --- | --- | --- |
| Subretinal fibrosis present, baseline | “2.8% (6 of 211)” | “1.4% (3 of 216)” |
| Subretinal fibrosis present, week 56 | “4.1% (8 of 193)” | “4.1% (8 of 197)” |
| Progression of fibrosis from baseline | “+ 46%” | “+ 193%” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

Additional sources: [EyePoint investor conferences and scientific meeting announcement (2026)](https://www.biospace.com/press-releases/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meeting)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Summary: ocular safety through week 56

Through week 56, the vorolanib insert arm (211 participants) and aflibercept arm (221 participants) had cataract in 4.3% and 5.4%, increased intraocular pressure in 3.8% and 3.2%, intraocular inflammation in 0.5% and 0.5%, and retinal detachment in 0.5% and 0.5% of participants. Ocular adverse events reported more often with the vorolanib insert included conjunctival hemorrhage (11.4% versus 5.0%), vitreous floaters (9.0% versus 3.6%), neovascular AMD (7.1% versus 1.4%), retinal hemorrhage (4.7% versus 1.8%), retinal edema (2.8% versus 0.9%), and visual impairment (2.4% versus 0.0%). No insert migration into the anterior chamber, anterior chamber opacities, free-floating particles, retinal vasculitis, or severe intraocular inflammation were reported. Serious adverse events, systemic adverse events, and endophthalmitis counts were not reported numerically; endophthalmitis was reported at less than 1% in both arms.

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.5-2"></a>

###### Adverse events of particular interest and events not observed

> “No cases of: Insert migration into the anterior chamber Anterior chamber opacities Free-floating particles Retinal vasculitis (occlusive or non-occlusive) Severe intraocular inflammation AEs of particular interest – all <1% in both arms: Retinal detachment Intraocular inflammation Endophthalmitis All cases of floaters were mild or moderate with no required treatment or impact on vision”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### Ocular adverse events in the study eye occurring in 2% or more of participants through week 56

| Adverse event | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg (n=221) |
| --- | --- | --- |
| Conjunctival haemorrhage | “11.4%” | “5.0%” |
| Vitreous floaters | “9.0%” | “3.6%” |
| Neovascular age-related macular degeneration | “7.1%” | “1.4%” |
| Retinal haemorrhage | “4.7%” | “1.8%” |
| Vitreous detachment | “4.7%” | “4.1%” |
| Cataract | “4.3%” | “5.4%” |
| Dry eye | “4.3%” | “6.3%” |
| Posterior capsule opacification | “4.3%” | “2.3%” |
| Intraocular pressure increased | “3.8%” | “3.2%” |
| Visual acuity reduced | “3.8%” | “5.4%” |
| Retinal oedema | “2.8%” | “0.9%” |
| Visual impairment | “2.4%” | “0.0%” |
| Dry age-related macular degeneration | “2.4%” | “3.2%” |
| Eye pain | “2.4%” | “0.9%” |
| Subretinal fluid | “2.4%” | “1.4%” |

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.1.8.5-4"></a>

###### Selected ocular adverse events including geographic atrophy

| Adverse event | DURAVYU 2.7 mg (N=211) | Aflibercept 2 mg (N=221) |
| --- | --- | --- |
| Intraocular inflammation (IOI) | “0.5%” | “0.5%” |
| Geographic atrophy (lower-level term) | “2.4%” | “2.7%” |
| Retinal detachment | “0.5%” | “0.5%” |
| Vision loss in participant with retinal detachment | “-40 letters” | “+1 letter” |

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

> “Patient in DURAVYU arm required surgery after retinal detachment and experienced cataract progression and development of epiretinal membrane that led to vision loss.”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.5-5"></a>

###### Geographic atrophy onset and growth by reading center

> “GA Growth Rate Similar in DURAVYU-treated vs. Fellow Eyes”
> “New GA Onset Rate Higher in Aflibercept Arm”
> “Growth rate in mm2 per independent reading center 2 1.7 mm2 1.6 mm2”
> “Progression towards fovea was similar between groups”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.1.8.5-6"></a>

###### Interim masked safety reviews during the trial

> “The DSMC recommended that both the LUGANO and LUCIA trials continue as”
> “planned, with no modifications to the protocol.”

Source: [EyePoint Pharmaceuticals DSMC recommendation announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000119312525286961/d65451dex991.htm)

<a id="topic-3.1.1.8.5-7"></a>

###### Serious and systemic adverse events

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

- The primary endpoint was not met in the full dataset. Non-inferiority was shown only in an ad hoc analysis that removed 9 of 211 participants (4.3%) in the vorolanib insert arm whose loss of 15 or more letters was attributed by retina specialists to causes other than wet AMD; the same attribution identified 0 of 216 aflibercept participants, and p-values for this and all secondary analyses are nominal.
- The full-dataset treatment difference and its confidence interval, the multiplicity procedure, missing data handling, and the efficacy population definition have not been reported; results are topline, labeled preliminary and pending final analysis, and were not peer reviewed as of September 2026.
- The aflibercept arm had a 0.5% rate of 15-letter or greater loss, lower than the 2.7% to 7.7% rates the sponsor cited from earlier trials, while the vorolanib insert arm had 7.5%. The sponsor attributes the imbalance to chance and to baseline differences; this cannot be confirmed from one trial. LUCIA, the identical second trial, also did not meet the primary endpoint (difference -3.7 letters), and its rate of 15-letter or greater loss has not been reported in text.
- Baseline imbalances favored the aflibercept arm on some risk factors for vision loss unrelated to neovascular activity: glaucoma history 11.4% versus 5.9%, total CNV area 5.69 versus 4.60 mm2, and geographic atrophy located closer to the fovea (825 versus 1009 µm); eligibility excluded only center-subfield atrophy.
- Vorolanib insert participants received three aflibercept loading doses before the first insert, supplemental aflibercept was available in both arms, and the supplement criteria wording differs between 2025 and 2026 company presentations; the efficacy therefore reflects a regimen of aflibercept loading plus insert plus supplemental aflibercept, not insert monotherapy.
- The comparator was fixed aflibercept 2 mg every 8 weeks, not treat-and-extend dosing, faricimab, or aflibercept 8 mg, and all 76 registry sites were in the United States.
- Efficacy is reported to week 56 only; year 2 was designed as a safety-only continuation, and EyePoint stated on November 12, 2026, that it will conclude the wet AMD program before completion of the full second year, so year 2 safety follow-up will be incomplete; no patient-reported outcome or quality-of-life data have been reported, and systemic and serious adverse event data are not yet public.
- Treatment burden was compared with a fixed aflibercept schedule that allows a maximum 60% reduction, so the 42% reduction measures scheduled injection frequency rather than burden relative to extended-interval regimens.

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [ClinicalTrials.gov NCT06668064](https://clinicaltrials.gov/study/NCT06668064); [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf); [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/); [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm); [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm)

<a id="heading-3.1.2"></a>

#### 3.1.2 LUCIA

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registered study summary

> “This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.”

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.1-2"></a>

###### Program objective: similar vision with dosing every 6 months and lower treatment burden

> “Objective: Demonstrate that EYP-1901, when administered every 6 months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden in patients with nAMD”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

<a id="topic-3.1.2.1-3"></a>

###### Role in the planned New Drug Application after LUGANO

> “Submit comprehensive Phase 3 data package (LUGANO & LUCIA) to FDA, including pooled data H1 2027”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

> “We look forward to a potential New Drug Application (NDA) filing with FDA in the first half of 2027, pending LUCIA results in the fourth quarter of 2026.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Summary: sites and timeline

The ClinicalTrials.gov record (last updated 2026-09-03) lists 113 locations: 78 in the United States, 7 in Israel, 7 in Poland, 6 in India, 5 in Brazil, 4 in Hungary, 3 in Czechia, and 1 each in Germany, Slovakia, and the United Kingdom. The 2025 enrollment completion announcement also names participation in Australia, which the registry does not list. The first participant was dosed in December 2024 (registry study start 2024-11-27), enrollment was completed on July 29, 2025, the registry estimated primary completion for 2026-10 and study completion for 2027-10, and topline results were announced on October 19, 2026. The same day, EyePoint announced that it would conclude the trial early, without full completion of its second year.

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742); [EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-ex99_1.htm); [EyePoint Pharmaceuticals LUCIA first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/eypt-ex99_1.htm); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm); [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm)

<a id="topic-3.1.2.2-2"></a>

###### Registry dates

| Milestone | Registry record |
| --- | --- |
| Study start (actual) | “2024-11-27” |
| Primary completion (estimated) | “2026-10” |
| Study completion (estimated) | “2027-10” |

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.2-3"></a>

###### Countries

> “LUCIA also marked our expansion beyond the U.S. with patient participation in South America, Europe, Israel, Australia and India, demonstrating global momentum and interest in DURAVYU.”

Source: [EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-ex99_1.htm)

> “We expect continued strong momentum, with sites outside the US now actively enrolling along with select LUGANO sites preparing to cross over to LUCIA.”

Source: [EyePoint Pharmaceuticals LUGANO enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025077373/eypt-ex99_1.htm)

<a id="topic-3.1.2.2-4"></a>

###### First participant dosed

> “today announced that the first patient has been dosed in the LUCIA trial, the Company’s second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD).”

Source: [EyePoint Pharmaceuticals LUCIA first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/eypt-ex99_1.htm)

<a id="topic-3.1.2.2-5"></a>

###### Enrollment completion

> “We successfully completed enrollment in our two pivotal Phase 3 clinical trials: the LUGANO trial on May 27, 2025, and the LUCIA trial on July 29, 2025.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-3.1.2.2-6"></a>

###### Expected topline results

> “The Company remains on track to report topline data from the second wet AMD pivotal Phase 3 LUCIA trial in the fourth quarter of 2026.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

<a id="topic-3.1.2.2-7"></a>

###### Topline results announced October 19, 2026, and early conclusion of the trial

> “WATERTOWN, Mass., October 19, 2026 (GLOBE NEWSWIRE)”
> “today announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of DURAVYU”

Source: [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm)

> “to conclude the pivotal Phase 3 wet AMD trials early, without full completion of the second year of each trial.”

Source: [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 3, randomized, double-masked, parallel-group, aflibercept-controlled design

> “A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD”

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.3-2"></a>

###### Identical design to LUGANO

> “LUGANO and LUCIA are identical, randomized, double-masked, aflibercept controlled, non-inferiority Phase 3 trials assessing the efficacy and safety of DURAVYU in patients with active wet AMD including both treatment naïve and treatment experienced patients.”
> “At Day 1, patients are randomized 1:1 to receive either DURAVYU 2.7mg every six months or on-label aflibercept as control.”

Source: [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm)

> “The LUCIA trial enrolled a very similar patient population, although the trial was slightly larger, at 475 patients. But the protocol is essentially identical.”

Source: [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/)

<a id="topic-3.1.2.3-3"></a>

###### Aflibercept loading, sham masking, and 24-month safety follow-up

> “All participants will receive 3 loading doses of aflibercept”
> “Sham injections used for masking”
> “On-label aflibercept control group”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

> “In June 2024, we announced alignment on pathway to approval with U.S. Food and Drug Administration (FDA) based on positive End of Phase 2 meeting in April 2024 for two non-inferiority trials, 6-month redosing of DURAVYU™ and sham for masking with a one-year endpoint.”
> “Safety evaluation only will be continued through year two of the trials.”

Source: [EyePoint Pharmaceuticals Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025034601/eypt-20241231.htm)

<a id="topic-3.1.2.3-4"></a>

###### Independent Data Safety Monitoring Committee

> “DSMC meetings are scheduled to occur every six months per the trial protocol, and this is the last anticipated DSMC meeting ahead of topline data.”

Source: [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key inclusion criteria

| Criterion | Quoted registry text |
| --- | --- |
| Minimum age | “50 Years” |
| Diagnosis and prior treatment status | “Previously treated or treatment naïve patients with a documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit.” |
| Visual acuity in the study eye | “Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score between 78 to 35 letters (approximately 20/32 to 20/200 Snellen equivalent) in the study eye at the Screening Visit and on Baseline (Day 1).” |
| Previously treated participants | “For previously-treated subjects, must have been treated with at least 2 anti-VEGF IVT injections (i.e., aflibercept 2 mg, aflibercept 8 mg, bevacizumab, ranibizumab, or faricimab) in the previous 6 months for wAMD per standard of care in the study eye prior to the Screening Visit.” |

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.4-2"></a>

###### Key exclusion criteria

> “Subfoveal fibrosis, atrophy, or scarring in the center subfield”
> “Fellow eye BCVA <20 letters (20/400 Snellen equivalent)”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

<a id="topic-3.1.2.4-3"></a>

###### Planned mix of treatment-naive and previously treated participants

> “Trials include approximately 75% treatment-naïve and 25% previously treated patients.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Registered arms

| Arm | Arm label | Intervention |
| --- | --- | --- |
| Experimental | “EYP-1901 2686 µg” | “Intravitreal Injection” |
| Active comparator | “Aflibercept” | “Aflibercept (2.0 mg)” |

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.5-2"></a>

###### Dosing schedule: vorolanib insert every 6 months from month 2

> “Patients in the DURAVYU treatment arm will receive an intravitreal injection of DURAVYU every six months, starting at month two of the trial.”

Source: [EyePoint Pharmaceuticals LUCIA first patient dosed announcement (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024133076/eypt-ex99_1.htm)

> “Patients in the DURAVYU 2.7mg treatment arm will be re-dosed every six months for a total of four doses over the two-year trial.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

<a id="topic-3.1.2.5-3"></a>

###### Supplemental aflibercept criteria

> “Supplemental aflibercept per prespecified criteria (all arms)”
> “BCVA reduction of ≥5 letters from best on-study measurement due to nAMD AND CST increase of ≥75 microns on SD-OCT from lowest on-study measurement”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

> “> 5 letter drop with 75 microns new fluid from AMD compared to best on study, or new, sight threatening hemorrhage due to wet AMD”

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm)

<a id="topic-3.1.2.5-4"></a>

###### Dosing visits reached during the trial

> “As of May 2, 2026, all active patients in the treatment arm have reached the Week 32 visit, during which patients received their second DURAVYU dose. Over 35% of those patients have also received their third planned dose at Week 56.”

Source: [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Mean Change in Best Corrected Visual Acuity as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Summary: rationale for the endpoint and margin

LUCIA uses the same primary endpoint and -4.5-letter margin as LUGANO. The sponsor cites non-inferiority margin precedent from recent FDA approvals in neovascular AMD, and published phase 3 trials in neovascular AMD used margins of 4.5 letters (Archway, port delivery system with ranibizumab) or 4 letters (TENAYA and LUCERNE, faricimab; PULSAR, aflibercept 8 mg).

Source: [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm); [Holekamp et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34597713/); [Heier et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35085502/); [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="topic-3.1.2.6.1-2"></a>

###### Registered outcomes

| Outcome type | Measure | Time frame |
| --- | --- | --- |
| Primary | “Average change in best corrected visual acuity (BCVA)” | “Weeks 52 and 56” |
| Secondary | “Rate of injection burden” | “Week 56” |
| Secondary | “Average change in best corrected visual acuity (BCVA)” | “Week 96” |

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.6.1-3"></a>

###### Primary endpoint and non-inferiority margin of 4.5 letters

> “LUGANO & LUCIA Follow Established Non-Inferiority Regulatory Path in Wet AMD Endpoints Primary Endpoint: Non-inferior (NI) mean change in BCVA from Day 1 to Week 52 and Week 56 (blended) vs aflibercept control (NI margin of -4.5 letters)”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.2.6.1-4"></a>

###### Secondary endpoints

> “Primary endpoint Difference in mean change in BCVA from Day 1 to W52 and 56 (averaged) vs aflibercept control”
> “Secondary endpoints • Safety • Reduction in treatment burden • Percent of eyes supplement-free • Anatomical stability”

Source: [Dinah and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_LUGANO-LUCIA_25091001.pdf)

<a id="topic-3.1.2.6.1-5"></a>

###### PULSAR: sample size assumptions and noninferiority test results at the four-letter margin

> “A SD of 13·6 letters was assumed for each group. Assuming a dropout rate of 10% by week 48, approximately 320 patients were planned for each group.”
> “The aflibercept 8q12 and 8q16 groups met the primary efficacy endpoint and showed non-inferior BCVA gains compared with the aflibercept 2q8 group, based on a non-inferiority margin of 4 letters”
> “The estimated difference in least square mean changes from baseline to week 48 in BCVA for aflibercept 8q12 versus 2q8 was –0·97 (95% CI –2·87 to 0·92; noninferiority test at four-letter margin: p=0∙0009) and for aflibercept 8q16 versus 2q8 was –1·14 (–2·97 to 0·69; p=0∙0011).”

Source: [Lanzetta et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38461841/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment

| Source field | Value |
| --- | --- |
| Registry enrollment (estimated) | “400” |

Source: [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742)

<a id="topic-3.1.2.7.1-2"></a>

###### Enrolled and randomized participants

> “The LUGANO trial enrolled 432 patients and the LUCIA trial enrolled 475 patients who were randomly assigned, 1:1, to a DURAVYU 2.7mg arm or an on-label aflibercept control arm.”

Source: [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm)

> “The LUCIA trial has enrolled and randomized over 400 patients in seven months making DURAVYU one of the fastest enrolling Phase 3 pivotal programs in wet AMD.”

Source: [EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-ex99_1.htm)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants analyzed

| Analysis | DURAVYU 2.7 mg | Aflibercept 2 mg |
| --- | --- | --- |
| Baseline characteristics table | “DURAVYU 2.7mg (n=232)” | “Aflibercept 2mg q8W (n=238)” |
| Ocular adverse event table | “DURAVYU 2.7mg (n=232)” | “Aflibercept 2mg (n=243)” |

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Analysis plan informed by LUGANO results

> “Includes learnings from LUGANO for the LUCIA analysis plan, ahead of topline results”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="topic-3.1.2.7.2-2"></a>

###### Analysis populations, model, and multiplicity control

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline characteristics by arm

| Characteristic | DURAVYU 2.7 mg (n=232) | Aflibercept 2 mg every 8 weeks (n=238) |
| --- | --- | --- |
| Age (years), mean (SD) | “76.8 (8.4)” | “77.2 (8.5)” |
| Female, n (%) | “144 (62.1)” | “129 (54.2)” |
| Treatment naive, n (%) | “176 (75.9)” | “179 (75.2)” |
| Previously treated, n (%) | “56 (24.1)” | “59 (24.8)” |
| BCVA (ETDRS letters), mean (SD) | “65.0 (10.0)” | “64.5 (10.3)” |
| Central subfield thickness (µm), mean (SD) | “314.8 (76.5)” | “318.3 (82.3)” |

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Summary: primary and key secondary efficacy results

LUCIA did not meet its primary endpoint of non-inferiority (margin -4.5 letters) in mean BCVA change from baseline to blended weeks 52 and 56. Least squares mean BCVA change was +2.5 letters with the vorolanib insert and +6.1 letters with aflibercept 2 mg every 8 weeks (difference -3.7 letters), with the confidence interval outside the 4.5-letter margin; the confidence interval itself was not reported in text. Mean injections after loading through week 56 were 3.3 with the insert and 5.3 with aflibercept, a 38% reduction (nominal p<0.0001). Supplement-free rates in the insert arm were 70% up to week 32 and 52% up to week 56, and 94% and 71% of insert participants received zero or one supplemental injection over the same periods. Mean central subfield thickness change through week 56 was -66 µm with the insert and -82 µm with aflibercept (difference +16 µm; nominal p=0.002). All results are labeled preliminary and pending final analysis.

Source: [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm); [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary endpoint: mean change in BCVA

> “In LUCIA, despite demonstrating visual improvement, DURAVYU did not achieve the primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) versus on-label 2 mg aflibercept control.”

Source: [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm)

| Measure | Quoted result |
| --- | --- |
| Aflibercept 2 mg every 8 weeks | “+6.1 letters” |
| DURAVYU 2.7 mg every 24 weeks | “+2.5 letters” |
| Difference | “Difference -3.7 letters” |
| Non-inferiority | “DURAVYU did not meet non-inferiority (CI outside 4.5 letters)” |
| Data status | “Preliminary data – pending final analysis” |

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-3.1.2.8.3-3"></a>

###### Treatment burden and supplement-free rates

> “Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value <0.0001), with 52% of eyes supplement-free and 71% receiving zero or one supplement up to Week 56, as well as strong anatomic control”

Source: [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm)

| Measure | Quoted result |
| --- | --- |
| Total injections after loading doses, aflibercept and DURAVYU | “5.3 3.3” |
| Treatment burden reduction | “38% Fewer Injections” |
| Supplement-free patients, up to week 32 and week 56 | “Supplement-Free Patients 70% 52%” |
| Patients with 0 or 1 supplement, up to week 32 and week 56 | “Patients with 0 or 1 Supplement 94% 71%” |

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-3.1.2.8.3-4"></a>

###### Central subfield thickness

| Measure | Quoted result |
| --- | --- |
| Aflibercept 2 mg every 8 weeks | “-82 µm” |
| DURAVYU 2.7 mg every 24 weeks | “-66 µm” |
| Difference | “Difference +16 µm” |
| Nominal p-value | “Nominal p=0.002” |

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-3.1.2.8.3-5"></a>

###### Sponsor expectation of regression to the mean in 15-letter losses

> “If LUCIA shows a regression to the mean in 15-letter losers, then we would be confident that our drug would be shown to be noninferior.”

Source: [Duker (2026)](https://retinalphysician.com/issues/2026/july-august/interpreting-the-lugano-trial/)

> “Modeling demonstrates impact of control arm overperformance and supports potential regression-to-the-mean for LUCIA”

Source: [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Interim masked safety across LUGANO and LUCIA

> “Interim masked safety data from the Phase 3 trials show a continued favorable safety profile for DURAVYU, consistent with the safety observed in over 190 patients across four completed clinical trials.”

Source: [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm)

> “The Company also announced that based on interim masked safety data, the safety profile observed in LUGANO and LUCIA is consistent with previous DURAVYU clinical trials.”

Source: [EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-ex99_1.htm)

<a id="topic-3.1.2.8.5-2"></a>

###### Unmasked LUCIA safety results

> “AEs of particular interest – all <1% in both arms: Severe intraocular inflammation Endophthalmitis”
> “Low patient discontinuation rate of ~8% through Week 56 in each arm”
> “No study or treatment discontinuations were related to DURAVYU”

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Ocular adverse events in the study eye occurring in 2% or more of participants through week 56

| Adverse event | DURAVYU 2.7 mg (n=232) | Aflibercept 2 mg (n=243) |
| --- | --- | --- |
| Conjunctival haemorrhage | “9.1%” | “3.7%” |
| Vitreous floaters | “8.2%” | “2.1%” |
| Cataract | “4.7%” | “5.3%” |
| Retinal haemorrhage | “4.7%” | “1.2%” |
| Intraocular pressure increased | “4.3%” | “2.5%” |

Source: [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

- LUCIA results are topline sponsor reports from October 19, 2026, labeled preliminary and pending final analysis; the confidence interval for the primary endpoint difference, serious and systemic adverse events, and the rate of 15-letter or greater vision loss have not been reported in text.
- The baseline characteristics table includes 232 insert and 238 aflibercept participants and the adverse event table 232 and 243 (475 randomized); the analysis population for the primary endpoint has not been reported.
- EyePoint announced on October 19, 2026, that it would conclude both phase 3 wet AMD trials early, without full completion of the second year of each trial, and restated on November 12, 2026, that it will conclude the wet AMD program before completion of the full second year, so planned year 2 safety follow-up will be incomplete.
- The sponsor states that learnings from LUGANO were included in the LUCIA analysis plan before LUCIA topline results; the content of these changes has not been disclosed, and changes made after results of an identical trial are known may affect how the LUCIA primary analysis is interpreted.
- The design is identical to LUGANO, so the same design limitations apply: three aflibercept loading doses before the first insert, supplemental aflibercept in both arms, a fixed aflibercept 2 mg every 8 weeks comparator, a -4.5-letter margin, efficacy assessed to week 56 with safety-only follow-up in year 2, and exclusion of only center-subfield atrophy.
- Enrollment (475 participants) exceeded the registry estimate of 400, and the registry lists 113 sites in 10 countries, 78 (69.0%) of them in the United States; the registry does not list Australia, which the sponsor named as a participating country.
- Neither LUGANO nor LUCIA met the prespecified primary endpoint, so no phase 3 trial has shown non-inferiority in BCVA to aflibercept 2 mg every 8 weeks in its full dataset.

Source: [EyePoint LUCIA topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_1.htm); [EyePoint LUCIA topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-ex99_2.htm); [EyePoint strategic prioritization announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-ex99_1.htm); [EyePoint LUGANO expanded results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526387197/eypt-ex99_1.htm); [EyePoint LUGANO topline results presentation (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_2.htm); [EyePoint LUGANO topline results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-ex99_1.htm); [ClinicalTrials.gov NCT06683742](https://clinicaltrials.gov/study/NCT06683742); [EyePoint Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526093917/eypt-20251231.htm); [EyePoint Pharmaceuticals phase 3 enrollment completion announcement (2025)](https://www.sec.gov/Archives/edgar/data/1314102/000095017025099383/eypt-ex99_1.htm); [EyePoint DSMC recommendation announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526222750/eypt-ex99_1.htm); [EyePoint third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1314102/000119312526456889/eypt-ex99_1.htm)

<a id="heading-3.1.3"></a>

#### 3.1.3 DAVIO 2

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Registered study objective

> “This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.”

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.1-2"></a>

###### Role of DAVIO 2 in the development program

> “the DAVIO 2 clinical trial was designed to support the initiation of Phase 3 clinical trials based on feedback received from the U.S. Food and Drug Administration (FDA) at a Type C meeting last year.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

<a id="topic-3.1.3.1-3"></a>

###### Post hoc analysis objective: supplemental injection patterns

> “OBJECTIVE: Understand patterns of supplemental injections in DAVIO 2”

Source: [Sheth et al. (2024)](https://eyepointpharma.com/wp-content/uploads/2025/02/ASRS-2024_DAVIO2-Wk32-Supplemental-Txt_Sheth_Presentation_24071601.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Sites and study period

> “This Phase 2 prospective, randomized, double-masked study was conducted in previously treated subjects with wet age-related macular degeneration (wAMD) at 39 sites in the United States between 30 June 2022 and 24 April 2024.”

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.2-2"></a>

###### Registry dates

| Field | Quoted record |
| --- | --- |
| First submitted | “2022-05-09” |
| Results first posted | “2025-10-02” |

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.2-3"></a>

###### Completion of enrollment

> “The trial exceeded its original target of 144 patients, enrolling a total of 160 patients.”

Source: [EyePoint Pharmaceuticals DAVIO 2 enrollment completion announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023009850/eypt-ex99_1.htm)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Registered design

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Primary purpose | “Treatment” |
| Study periods | “This study consists of a screening period (up to 14 days) and treatment period (56 weeks).” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.3-2"></a>

###### Masking and on-label comparator

> “Design: Multi-center, randomized, double-masked trial in patients with previously treated wet AMD”
> “Aflibercept on-label control required by FDA”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results presentation (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_2.htm)

<a id="topic-3.1.3.3-3"></a>

###### Prespecified supplemental aflibercept criteria

> “BCVA reduction ≥5 letters from best on-study measurement due to wet AMD AND CST increase ≥75 µm from lowest on-study measurement”
> “BCVA reduction ≥10 letters from best on-study measurement due to wet AMD”
> “CST increase ≥100 µm from lowest on-study measurement from 2 consecutive visits”
> “Vision-threatening hemorrhage, new or worsening, due to wet AMD”

Source: [Sheth et al. (2024)](https://eyepointpharma.com/wp-content/uploads/2025/02/ASRS-2024_DAVIO2-Wk32-Supplemental-Txt_Sheth_Presentation_24071601.pdf)

<a id="topic-3.1.3.3-4"></a>

###### Definition of supplemental therapy

> “Supplemental therapy was any unscheduled injection of aflibercept, whether or not a subject had met rescue criteria.”
> “For either of the EYP-1901 arms, any aflibercept injection following the Week 8 visit was supplemental therapy.”

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.3-5"></a>

###### Design changes between the 2022 plan and the conducted trial

> “Diagnosed within past 9 months”
> “Central subfield thickness > 400 µm”
> “Retinal pigment epithelium detachment thickness > 300 µm”

Source: [EyePoint Pharmaceuticals Investor Day presentation (2022)](https://www.sec.gov/Archives/edgar/data/1314102/000095017022012766/eypt-ex99_2.htm)

> “Diagnosed with wAMD at any time”
> “Excluded CST >350 µm, IRF >25 µm, RPED >400 µm”

Source: [Regillo (2024)](https://eyepoint.bio/wp-content/uploads/2025/02/AAOSSD-2024_DAVIO2-1yr_Regillo_Presentation.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion criteria

> “Documented diagnosis of wAMD in the study eye, with disease onset any time prior to the Screening Visit.”
> “Previously treated with at least 2 anti-VEGF intravitreal injections (that is, bevacizumab, ranibizumab, aflibercept or faricimab) for wAMD per standard of care in the study eye within 6 months prior to the Screening Visit.”
> “Best corrected visual acuity (BCVA) early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 85 letters (20/20 Snellen equivalent) in the study eye at the Screening Visit and on Day 1.”

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.4-2"></a>

###### Key ocular exclusion criteria

> “Central subfield thickness (CST) >350 micrometer (mcm) in the study eye at the Screening Visit or Day 1.”
> “Previous treatment with intravitreal corticosteroid injection or device implantation in the study eye.”

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.4-3"></a>

###### Key systemic exclusion criteria

> “Myocardial infarction within 6 months prior to screening or New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled atrial fibrillation, uncontrolled angina, cardiomyopathy, ventricular arrhythmias or other cardiac conditions which, in the judgment of the investigator, could make the subject inappropriate for entry into this study.”
> “Glycated hemoglobin (HbA1c) greater than 7% at the Screening Visit.”

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment arms

| Arm | Quoted record |
| --- | --- |
| Aflibercept 2 mg | “Subjects received aflibercept 2 mg intravitreal injection on Day 1 and at Week 4 followed by intravitreal injection of aflibercept 2 mg and sham injection at Week 8 and then aflibercept 2 mg intravitreal injection once every 8 weeks up to Week 56.” |
| EYP-1901 2060 mcg | “Subjects received aflibercept 2 mg intravitreal injection on Day 1 and at Week 4 followed by intravitreal injection of aflibercept 2 mg and EYP-1901 2060 mcg injection at Week 8 and then intravitreal sham injection once every 8 weeks up to Week 56.” |
| EYP-1901 3090 mcg | “Subjects received aflibercept 2 mg intravitreal injection on Day 1 and at Week 4 followed by intravitreal injection of aflibercept 2 mg and EYP-1901 3090 mcg injection at Week 8 and then intravitreal sham injection once every 8 weeks up to Week 56.” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.5-2"></a>

###### Relation of the phase 2 doses to the phase 3 dose

> “EYP-1901 dosing likely 1 or 2 inserts (vs 2 or 3 in DAVIO 2)”

Source: [EyePoint Pharmaceuticals investor presentation (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/eypt-ex99_1.htm)

> “The dose investigated in phase 3 trials is 2.7 mg (two inserts of 1.343 mg each) administered in a single injection.”

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Best-Corrected Visual Acuity as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint

> “Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32”

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.6.1-2"></a>

###### Noninferiority margin

> “The lower limit of the non-inferiority margin is defined as a -4.5 letters by the FDA with 5 letters representing one line on the eye chart.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

<a id="topic-3.1.3.6.1-3"></a>

###### Secondary endpoints

> “Secondary endpoints include safety, change in CST as measured by OCT, the number of eyes that remain free of supplemental anti-VEGF injections, and number of aflibercept injections in each group.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

<a id="topic-3.1.3.6.1-4"></a>

###### Post hoc BCVA time-in-range analysis

> “TIR was defined as the cumulative duration in days between visits during which the BCVA absolute letter score remained at or above the threshold”
> “≥ 69 letters (~20/40 SE, minimum driving requirement in most US states)”

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned and enrolled participants

> “Originally designed to enroll 144 patients, the trial enrolled 160 patients in total due to strong investigator and patient interest.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

> “A total of 161 subjects were randomized in the study.”

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.7.1-2"></a>

###### Participants by analysis population

| Population | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| Started | “54” | “53” | “54” |
| Baseline and primary endpoint analysis (full analysis set) | “54” | “50” | “52” |

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Full analysis and safety sets as registered

> “Full Analysis Set (FAS) included all randomized subjects who received at least 1 dose of study treatment.”
> “The Safety analysis set included all subjects who received at least 1 dose of study treatment.”

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.7.2-2"></a>

###### Full analysis set as presented at congresses

> “Values reflect baseline characteristics of Full Analysis Set (n=156), defined as patients who received both Day 1 and Week 8 treatments.”

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="topic-3.1.3.7.2-3"></a>

###### Participants excluded from the full analysis set

> “One patient was randomized but later determined to be a screen failure and never received treatment.”
> “Five patients (3 in the EYP-1901 2 mg group and 2 in the EYP-1901 3 mg group) did not receive their Week 8 treatment.”

Source: [Wykoff (2024a)](https://eyepoint.bio/wp-content/uploads/2025/02/Angiogenesis-2024_DAVIO-2-Topline-Deck_16Jan2024.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Primary analysis model

> “Mixed Model for Repeated Measures (MMRM)”

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.7.2-5"></a>

###### Handling of missing visit data in supplement-free analyses

> “Response at each visit calculated for only patients with nonmissing data at that visit.”

Source: [Sheth et al. (2024)](https://eyepointpharma.com/wp-content/uploads/2025/02/ASRS-2024_DAVIO2-Wk32-Supplemental-Txt_Sheth_Presentation_24071601.pdf)

<a id="topic-3.1.3.7.2-6"></a>

###### Median time to first supplemental injection: censoring

> “The upper limit of the 95% confidence interval for the median was not available due to an insufficient number of observed events (ie, the first supplemental aflibercept injections) occurring after the median time point.”

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Disposition through week 56

| Milestone or reason | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| Started | “54” | “53” | “54” |
| Completed | “52” | “47” | “52” |
| Not completed | “2” | “6” | “2” |
| Adverse event: ocular, study eye | “0” | “1” | “0” |
| Adverse event: non-ocular | “0” | “1” | “0” |
| Lost to follow-up | “1” | “0” | “0” |
| Protocol deviation | “0” | “2” | “0” |
| Withdrawal by subject | “1” | “0” | “1” |
| Death | “0” | “2” | “0” |
| Discontinued study without receiving study drug | “0” | “0” | “1” |

Source: [ClinicalTrials.gov NCT05381948](https://clinicaltrials.gov/study/NCT05381948)

<a id="topic-3.1.3.8.1-2"></a>

###### Discontinuations up to week 32

> “Patient discontinuation up to week 32 was low at 4%.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics: full analysis set

| Characteristic | Aflibercept 2 mg, 54 participants | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
| --- | --- | --- | --- |
| Age, mean (SD), years | “75.9(7.59)” | “76.4(6.66)” | “75.4(7.19)” |
| Female | “29” | “32” | “35” |
| White | “53” | “50” | “51” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

###### Ocular characteristics and prior treatment: full analysis set

| Characteristic | EYP-1901 2 mg, 50 participants | EYP-1901 3 mg, 52 participants | Aflibercept every 8 weeks, 54 participants |
| --- | --- | --- | --- |
| BCVA, mean (range), letters | “73.9 (52–84)” | “74.9 (46–85)” | “73.4 (41–85)” |
| CST, mean (range), µm | “264.5 (192–400)” | “262.9 (186–345)” | “265.7 (178–348)” |
| Duration of neovascular AMD, mean (range), years | “2.0 (0.1–7.9)” | “2.2 (0.2–10.8)” | “2.2 (0.2–20.2)” |
| Anti-VEGF injections per 12 months, normalized mean (range) | “9.8 (2–13)” | “10.0 (2–13)” | “9.5 (2–13)” |

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Summary: DAVIO 2 efficacy through week 56

DAVIO 2 randomized 161 participants; the full analysis set included 156 (54 aflibercept 2 mg every 8 weeks, 50 EYP-1901 2060 mcg, 52 EYP-1901 3090 mcg). For the primary endpoint (BCVA change averaged over weeks 28 and 32), the registry reports least-squares mean changes of 1.17, 1.05, and 0.87 letters, with differences versus aflibercept of -0.12 letters (95% CI, -2.48 to 2.24) for 2060 mcg and -0.31 letters (95% CI, -2.63 to 2.02) for 3090 mcg; both lower confidence limits were above the -4.5-letter noninferiority margin. EyePoint's topline release reported differences of -0.3 and -0.4 letters. At week 56, mean BCVA change was 1.1 letters with aflibercept, 0.3 letters with 2060 mcg, and -1.9 letters with 3090 mcg. Up to week 32, 62.5% and 63.5% of EYP-1901 participants received no supplemental aflibercept, compared with 94.3% of aflibercept participants; at week 56, the proportions were 42.6%, 46.2%, and 82.7%. The normalized number of aflibercept injections through week 56 was 3.45 and 3.36 in the EYP-1901 arms and 6.33 in the aflibercept arm.

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948); [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

<a id="topic-3.1.3.8.3-2"></a>

###### Primary endpoint: BCVA change averaged over weeks 28 and 32

| Statistic | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| Least-squares mean change, letters | “1.17” | “1.05” | “0.87” |
| Least-squares mean difference vs aflibercept, letters | Not applicable | “-0.12” | “-0.31” |
| 95% CI lower limit | Not applicable | “-2.48” | “-2.63” |
| 95% CI upper limit | Not applicable | “2.24” | “2.02” |
| P value | Not applicable | “0.919” | “0.795” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-3.1.3.8.3-3"></a>

###### Primary endpoint: company-reported topline result

> “Statistical non-inferiority in change in BCVA (at a confidence interval of 95%) compared to aflibercept control, at weeks 28 and weeks 32 combined. The 2mg and 3mg doses were only -0.3 and -0.4 letters different, respectively, versus on-label aflibercept.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

<a id="topic-3.1.3.8.3-4"></a>

###### BCVA mean change from baseline at weeks 32 and 56

| Visit | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| Baseline, mean letters | “73.4” | “73.9” | “74.9” |
| Week 32, mean change, letters | “1.6” | “1.0” | “0.8” |
| Week 56, mean change, letters | “1.1” | “0.3” | “-1.9” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-3.1.3.8.3-5"></a>

###### Categorical BCVA change at weeks 32 and 56

| Category, percentage of participants | Aflibercept 2 mg, 53 participants | EYP-1901 2060 mcg, 48 participants | EYP-1901 3090 mcg, 52 participants |
| --- | --- | --- | --- |
| Week 32, gain of 5 or more letters | “34.0” | “25.0” | “21.2” |
| Week 32, loss of 5 or more letters | “13.2” | “20.8” | “11.5” |
| Week 32, loss of 15 or more letters | “1.9” | “0” | “1.9” |
| Week 56, gain of 5 or more letters | “32.7” | “23.4” | “15.4” |
| Week 56, loss of 5 or more letters | “23.1” | “23.4” | “32.7” |
| Week 56, loss of 10 or more letters | “11.5” | “10.6” | “13.5” |
| Week 56, loss of 15 or more letters | “7.7” | “4.3” | “3.8” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-3.1.3.8.3-6"></a>

###### Categorical BCVA change at month 7/8: company-reported

> “No EYP-1901 patients had loss of ≥15 letters”

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="topic-3.1.3.8.3-7"></a>

###### Participants without supplemental aflibercept

| Visit, percentage of participants | Aflibercept 2 mg, 53 participants | EYP-1901 2060 mcg, 48 participants | EYP-1901 3090 mcg, 52 participants |
| --- | --- | --- | --- |
| Up to week 32 | “94.3” | “62.5” | “63.5” |
| Up to week 56 | “82.7” | “42.6” | “46.2” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-3.1.3.8.3-8"></a>

###### Median time to first supplemental aflibercept injection after week 8

| Statistic | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
| --- | --- | --- |
| Median, weeks | “37.00” | “40.79” |
| 95% CI | “(20.14 to NA)” | “(20.00 to NA)” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.8.3-9"></a>

###### Normalized aflibercept injections, including loading doses

| Visit, mean (SD) | Aflibercept 2 mg, 54 participants | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
| --- | --- | --- | --- |
| Week 32 | “3.23(0.357)” | “2.06(0.583)” | “2.13(0.747)” |
| Week 56 | “6.33(0.754)” | “3.45(1.738)” | “3.36(1.854)” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.8.3-10"></a>

###### Treatment burden compared with the pre-trial period

> “89% and 85% reduction in treatment burden, respectively, for the 2mg and 3mg EYP-1901 doses.”

Source: [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm)

> “EYP-1901 reduced treatment burden by ≥80% over 12 months vs pre-trial treatment”
> “63% at 6 months after EYP-1901 dosing”
> “44% at 12 months after EYP-1901 dosing”
> “About one-third of aflibercept q8W arm patients met criteria and received supplemental treatment”

Source: [Regillo (2024)](https://eyepoint.bio/wp-content/uploads/2025/02/AAOSSD-2024_DAVIO2-1yr_Regillo_Presentation.pdf)

<a id="topic-3.1.3.8.3-11"></a>

###### Reasons for supplemental injections up to week 32

> “24% (12/50) of EYP-1901 2 mg patients”
> “31% (16/52) of EYP-1901 3 mg patients”
> “Received supplemental injections per prespecified criteria”

Source: [Sheth et al. (2024)](https://eyepointpharma.com/wp-content/uploads/2025/02/ASRS-2024_DAVIO2-Wk32-Supplemental-Txt_Sheth_Presentation_24071601.pdf)

> “12% (6/50) of EYP-1901 2 mg patients”
> “6% (3/52) of EYP-1901 3 mg patients”
> “Received supplemental injections while never meeting prespecified criteria”
> “SRF increased: Accounted for half of injections not meeting any criteria”

Source: [Sheth et al. (2024)](https://eyepointpharma.com/wp-content/uploads/2025/02/ASRS-2024_DAVIO2-Wk32-Supplemental-Txt_Sheth_Presentation_24071601.pdf)

<a id="topic-3.1.3.8.3-12"></a>

###### Anatomic outcomes at weeks 32 and 56

| Measure | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| CST, baseline mean, µm | “265.7” | “264.5” | “262.9” |
| CST, week 32 mean change, µm | “5.4” | “17.8” | “10.6” |
| CST, week 56 mean change, µm | “8.1” | “12.2” | “16.7” |
| No detectable intraretinal fluid in the central subfield, week 32, % | “62.3” | “52.1” | “51.9” |
| No detectable intraretinal fluid in the central subfield, week 56, % | “59.6” | “59.6” | “51.9” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="topic-3.1.3.8.3-13"></a>

###### Subgroup: eyes without supplemental treatment through month 8

> “Among patients who did not receive supplemental injections, BCVA results were similar across arms”
> “Among patients who did receive supplemental injections, BCVA was stable with EYP-1901 through Month 8”

Source: [Sivaprasad et al. (2025)](https://eyepoint.bio/wp-content/uploads/2025/09/EURETINA2025_DAVIO-2_Vision-Outcomes_25091001.pdf)

| Arm | Supplement-free subgroup size |
| --- | --- |
| EYP-1901 3 mg | “EYP-1901 3 mg, n=33” |
| EYP-1901 2 mg | “EYP-1901 2 mg, n=30” |
| Aflibercept every 8 weeks | “Aflibercept q8W, n=46” |

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="topic-3.1.3.8.3-14"></a>

###### Subgroup: supplement-free eyes, BCVA difference versus aflibercept at month 7/8

| Arm | Mean change in BCVA vs aflibercept |
| --- | --- |
| EYP-1901 2 mg | “DURAVYU 2mg +0.6” |
| EYP-1901 3 mg | “DURAVYU 3mg +0.1” |

Source: [EyePoint Pharmaceuticals R&D Day presentation (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024077636/eypt-ex99_1.htm)

<a id="topic-3.1.3.8.3-15"></a>

###### Post hoc time-in-range analysis through week 32

> “One dose of EYP-1901 3 mg maintained vision ≥ 69 letters for 28 of 32 weeks”
> “In supplement-free patients, BCVA TIR results were similar across arms”

Source: [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

Additional sources: [Loewenstein et al. (2024)](https://eyepoint.bio/wp-content/uploads/2025/02/EURETINA2024_DAVIO2-1yr_Loewenstein_ePoster_FINAL-091824.pdf); [Abbey and Ribeiro (2025)](https://eyepoint.bio/wp-content/uploads/2025/10/AAO-2025_EYP-1901-DAVIO2-VERONA_25102001.pdf); [Shah (2026)](https://www.ophthalmologyadvisor.com/reports/single-dose-vorolanib-insert-matches-bimonthly-aflibercept-amd-vision-outcomes/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Participants with treatment-emergent adverse events through week 56

| Category | Aflibercept 2 mg, 54 participants | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
| --- | --- | --- | --- |
| Any TEAE, study eye | “30” | “30” | “30” |
| Any TEAE, fellow eye | “21” | “11” | “20” |
| Any TEAE, systemic | “40” | “28” | “39” |
| Serious TEAE, study eye | “2/54 (3.70%)” | “0/50 (0.00%)” | “4/52 (7.69%)” |
| Serious TEAE, fellow eye | “1/54 (1.85%)” | “0/50 (0.00%)” | “0/52 (0.00%)” |
| Serious TEAE, systemic | “6/54 (11.11%)” | “6/50 (12.00%)” | “9/52 (17.31%)” |
| All-cause mortality, systemic | “0/54 (0.00%)” | “2/50 (4.00%)” | “0/52 (0.00%)” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.8.5-2"></a>

###### Study eye serious adverse events: endophthalmitis

| Event, study eye | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| Endophthalmitis | “2/54 (3.70%)” | “0/50 (0.00%)” | “3/52 (5.77%)” |
| Non-infectious endophthalmitis | “0/54 (0.00%)” | “0/50 (0.00%)” | “1/52 (1.92%)” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

> “For the events of endophthalmitis in the Serious Adverse Events (SAE) table, none were considered related to EYP-1901. In the aflibercept treatment group, these events were considered related to the injection procedure or were not treatment-related. In the EYP-1901 treatment group, these events were considered related to the supplemental injection procedure (with aflibercept), the paracentesis for aqueous humor collection, or were not treatment-related.”

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.8.5-3"></a>

###### Study eye serious adverse events: investigator-reported timing (November 2023 data cut)

> “Retinal detachment at week 1; one week after initial aflibercept injection, prior to EYP-1901 injection”
> “Bacterial endophthalmitis at week 32; two days after anterior chamber paracentesis in a patient using CPAP”
> “Non-infectious endophthalmitis at week 29; seven days after aflibercept injection”
> “Retinal tears at week 36; four weeks after aflibercept injection”

Source: [EyePoint Pharmaceuticals investor presentation (2024)](https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/eypt-ex99_1.htm)

<a id="topic-3.1.3.8.5-4"></a>

###### Selected non-serious adverse events

| Event | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- | --- |
| Visual acuity reduced, study eye | “3/54 (5.56%)” | “1/50 (2.00%)” | “8/52 (15.38%)” |
| Vitreous floaters, study eye | “1/54 (1.85%)” | “2/50 (4.00%)” | “6/52 (11.54%)” |
| Hypertension, systemic | “4/54 (7.41%)” | “2/50 (4.00%)” | “7/52 (13.46%)” |

Source: [ClinicalTrials.gov NCT05381948 results](https://clinicaltrials.gov/study/NCT05381948?tab=results)

<a id="topic-3.1.3.8.5-5"></a>

###### Company-reported safety findings through end of study

> “No EYP-1901–related ocular SAEs or systemic SAEs”
> “No insert migration into the anterior chamber”
> “No cases of retinal occlusive vasculitis”
> “Six participants with ocular study eye SAEs – none deemed related to EYP-1901”

Source: [Regillo (2024)](https://eyepoint.bio/wp-content/uploads/2025/02/AAOSSD-2024_DAVIO2-1yr_Regillo_Presentation.pdf)

<a id="topic-3.1.3.8.5-6"></a>

###### Systemic and ocular exposure to EYP-1901

| Matrix and visit | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
| --- | --- | --- |
| Plasma, week 20, mean, pg/mL | “23.206” | “27.121” |
| Plasma, week 56, mean, pg/mL | “7.733” | “10.392” |
| Aqueous humor, week 20, mean, ng/mL | “17.426” | “25.066” |
| Aqueous humor, week 32, mean, ng/mL | “11.890” | “19.813” |

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

DAVIO 2 was a phase 2 trial with 50 to 54 participants per arm in the full analysis set, conducted at 39 sites in the United States, with 154 of 156 participants (98.7%) reported as White. Eligibility required a documented anatomic response to prior anti-VEGF therapy, at least 2 anti-VEGF injections in the prior 6 months, and CST of 350 µm or less, so treatment-naive eyes and eyes with greater baseline exudation were not studied. All arms received aflibercept loading at day 1, week 4, and week 8, including an aflibercept injection given with the EYP-1901 insert at week 8. The tested doses (2060 mcg and 3090 mcg, single administration) differ from the 2.7-mg dose given every 6 months in phase 3. The primary endpoint was measured 20 to 24 weeks after insert administration; the week 56 BCVA, supplement-free, and injection-count outcomes are descriptive secondary outcomes without reported hypothesis tests. Company presentations defined the full analysis set as participants who received both day 1 and week 8 treatments, whereas the registry describes it as participants who received at least 1 dose, and company-reported differences for the primary endpoint (-0.3 and -0.4 letters) differ from the registry least-squares differences (-0.12 and -0.31 letters). Several subgroup and time-in-range analyses were post hoc. No peer-reviewed full publication of DAVIO 2 was identified; most results come from sponsor press releases, sponsor-funded congress presentations, and the registry record.

Source: [ClinicalTrials.gov NCT05381948 API record](https://clinicaltrials.gov/api/v2/studies/NCT05381948); [EyePoint Pharmaceuticals DAVIO 2 topline results announcement (2023)](https://www.sec.gov/Archives/edgar/data/1314102/000095017023067468/eypt-ex99_1.htm); [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="heading-3.1.4"></a>

#### 3.1.4 DAVIO

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Primary and secondary objectives

> “The primary objective of this study was to evaluate the safety and determine the maximum tolerated dose of the EYP-1901 intravitreal insert for the treatment of patients with wAMD, based on ocular treatment-emergent adverse events (TEAEs) in the study and fellow eye, as well as nonocular adverse events (AEs), including clinical laboratory findings.”
> “Posthoc exploratory analyses were conducted to evaluate reduction in treatment burden and supplemental injection-free rate.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Sites and study period

> “The study was a phase I, multicenter (11 sites in the US), prospective, open-label, dose escalation trial.”
> “The study was conducted from January 2021 to May 2022.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.2-2"></a>

###### Registry dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2021-01-20” |
| Primary completion (actual) | “2022-05-11” |

Source: [ClinicalTrials.gov NCT04747197](https://clinicaltrials.gov/study/NCT04747197)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Dose-escalation design

> “All patients in the study received EYP-1901, and both patients and investigators were not masked.”
> “According to the study protocol, 3 successive dose cohorts were planned to be enrolled in the dose-escalation phase, and depending on toxicity, up to 26 patients could have been enrolled during this phase.”
> “The study duration was 48 weeks, and the study consisted of a patient screening phase and a sequential dose-escalation phase.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.3-2"></a>

###### Criteria for additional anti-VEGF injections

> “Administration of additional Food and Drug Administration-approved anti-VEGF treatment for wAMD (e.g., ranibizumab or aflibercept; not brolucizumab) or off-label bevacizumab was allowed at the investigator's discretion if a patient had a new or worsening vision-threatening hemorrhage since day 0 due to wAMD, an increase in CST of >75 μm from day 0, or a loss of ≥10 ETDRS letters from day 0 with intraretinal or subretinal fluid and/or hemorrhage judged to be the cause of BCVA loss.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key inclusion criteria

> “They must have received ≥3 prior injections with the same anti-VEGF agent (including bevacizumab, ranibizumab, or aflibercept) in the 6 months prior to the screening visit, in the study eye.”
> “Patients must have had best-corrected visual acuity (BCVA), using ETDRS charts, of 25 letters (Snellen equivalent, 20/320) to 85 letters (Snellen equivalent, 20/20).”
> “Notably, patients were not excluded based on fluid levels or CST-based criteria.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Single intravitreal administration after standard-of-care anti-VEGF

> “Patients received a single intravitreal administration of EYP-1901 in the study eye on day 0 using a preloaded applicator, 7 to 10 days following their last anti-VEGF injection.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.5-2"></a>

###### Dose cohorts as treated

> “Patients were assigned to 1 of 4 cohorts based on their received dose: 440 μg cohort (1 insert; n = 3), 1030 μg cohort (1 insert; n = 1), 2060 μg cohort (2 inserts; n = 8), 3090 μg cohort (3 inserts; n = 5).”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.5-3"></a>

###### Injector deviation in the high-dose cohort

> “Investigators experienced difficulties with the injector related to the advancement of the plunger as it pushed the 3 inserts (1030 μg each) through the needle.”
> “The injector issues that caused the deviation have been resolved in the subsequent phase II DAVIO 2 trial, and the device continues to be in development.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Ocular and Nonocular Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Registered primary and secondary outcomes

| Role | Quoted record |
| --- | --- |
| Primary outcome | “Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs)” |
| Secondary outcome | “Change in best corrected visual acuity (BCVA) by EDTRS” |
| Secondary outcome | “Mean change in central subfield thickness (CST)” |

Source: [ClinicalTrials.gov NCT04747197](https://clinicaltrials.gov/study/NCT04747197)

<a id="topic-3.1.4.6.1-2"></a>

###### Maintenance of BCVA and CST as the targeted efficacy signal

> “For this reason, patients who were already stable on anti-VEGF therapy were recruited for the DAVIO Trial. As a result, instead of the rapid improvement seen with typical anti-VEGF clinical trials in a treatment-naive population, the maintenance of stable BCVA and CST was targeted and observed in this study.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.6.1-3"></a>

###### Definition of treatment burden

> “Preenrollment and postenrollment treatment burden, defined as the number of injections during the 12-month period before or after the EYP-1901 injection, were derived for each patient.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Sample size

> “No formal sample size calculations were performed.”
> “All 17 patients were included in the safety analyses.”
> “As a result, all secondary and exploratory analyses included only the 16 patients who completed the study.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Descriptive analyses and exclusion of one participant

> “All safety, tolerability, and secondary and exploratory parameters were reported using descriptive summary statistics. No inferential statistical analysis was planned.”
> “Because no additional data were collected after week 16, the study sponsor decided to exclude this patient from the secondary and exploratory analyses to avoid the potential to skew the data.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.7.2-2"></a>

###### Normalization of pre-enrollment treatment burden

> “Patients who were treated for <12 months prior to study enrollment had their 12-month treatment burden normalized based on the number of injections they received and the time period during which they received those injections”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.7.2-3"></a>

###### Minimal-fluid subgroup definition

> “A subgroup of patients from the mid- and high-dose cohorts with minimal or no fluid at baseline, defined as CST values of ≤350 μm at screening (n = 9; CST, 205–298 μm) and minimal intraretinal or subretinal fluid reported in the study eye, was identified and analyzed separately.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Withdrawal and death of one participant

> “One patient withdrew from the study after the week 16 visit due to personal concerns related to traveling during the ongoing coronavirus disease 2019 pandemic.”
> “The cause of death was listed as diverticulitis, which was a preexisting condition reported in the patient’s previous medical history prior to the start of the study that had resolved and was not being treated at the time of screening per the patient’s own report.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline characteristics: all 17 participants

| Characteristic | Single-dose EYP-1901, 17 participants |
| --- | --- |
| Age, mean (range), years | “77.4 (67–94)” |
| Female, n (%) | “13 (76)” |
| BCVA, ETDRS letters, mean (range) | “69 (38–85)” |
| CST, µm, mean (range) | “299 (204–441)” |
| Time from diagnosis to enrollment, months, median (range) | “17 (4–74)” |
| Anti-VEGF injections in the prior 12 months, normalized, mean (range) | “8.6 (3–10)” |

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Summary: DAVIO biologic activity

In DAVIO, 17 participants with previously treated wet age-related macular degeneration received a single EYP-1901 injection at 440 to 3090 μg, and 16 were included in efficacy analyses. Mean BCVA change from baseline was -1.8 letters at 6 months and -5.4 letters at 12 months, and mean CST change was +1.7 μm and +2.4 μm. At 12 months, 6 of 16 participants (37.5%) had lost 5 or more letters. Treatment burden, compared with a normalized pre-enrollment count, was reduced by 74% at 6 months and 71% at 12 months. Of 16 study eyes, 13 (81%), 8 (50%), and 5 (31%) required no additional anti-VEGF injection up to 3, 6, and 12 months, respectively. The study had no control arm, was open label, and was not powered for efficacy.

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.3-2"></a>

###### BCVA change from baseline

> “A mean (range) BCVA change from baseline of +0.7 (−11 to +12), −5.2 (−51 to +10), −1.8 (−38 to +8), and −5.4 (−45 to +10) ETDRS letters was observed at 4, 5, 6, and 12 months, respectively, following administration of EYP-1901”
> “Among the 16 patients who completed the study, 6 (37.5%) had a loss of ≥5 letters from baseline in BCVA at 12 months, and 10 patients (62.5%) had a loss of <5 letters, no change, or a gain from baseline in BCVA at 12 months.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.3-3"></a>

###### CST change from baseline

> “A mean (range) CST change from baseline of +2.7 (−147 to +173), +60.5 (−91 to +227), +1.7 μm (−174 to +263), and +2.4 μm (−215 to +239) was observed at 4, 5, 6, and 12 months, respectively, following administration of EYP-1901”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.3-4"></a>

###### Treatment burden and injection-free rates

> “When comparing the number of anti-VEGF injections before and after treatment with EYP-1901, the treatment burden was reduced by 74% at 6 months and 71% at 12 months”
> “The median time to first additional anti-VEGF treatment was 6.5 months. Thirteen eyes of 16 (81%) remained additional-injection free up to 3 months, 8 of 16 (50%) up to 6 months, and 5 of 16 (31%) up to 12 months”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.3-5"></a>

###### Subgroup: minimal or no fluid at screening

> “In the subgroup of 9 eyes that had minimal or no fluid at screening, the mean change in BCVA from baseline was −0.4 letters (range, −12 to +8) at 6 months and −2.2 letters (range, −17 to +10) at 12 months.”
> “Sixty-seven percent did not require an additional injection up to 6 months and 56% up to 12 months. The median time to first additional anti-VEGF treatment among these eyes was 12 months.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.3-6"></a>

###### Earlier company-reported 12-month treatment burden

> “EYP-1901 Phase 1 DAVIO clinical trial continues clinically significant reduction in treatment burden of 74% at 12-months”

Source: [EyePoint Pharmaceuticals Investor Day presentation (2022)](https://www.sec.gov/Archives/edgar/data/1314102/000095017022012766/eypt-ex99_2.htm)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Summary of ocular TEAEs by dose

| TEAEs through study end, n (%) | 440 μg, 3 participants | 1030 μg, 1 participant | 2060 μg, 8 participants | 3090 μg, 5 participants | Overall, 17 participants |
| --- | --- | --- | --- | --- | --- |
| Participants with 1 or more ocular TEAE | “3 (100.0)” | “0 (0.0)” | “6 (75.0)” | “4 (80.0)” | “13 (76.5)” |
| Participants with 1 or more ocular treatment-related TEAE | “1 (33.3)” | “0 (0.0)” | “4 (50.0)” | “1 (20.0)” | “6 (35.3)” |
| Conjunctival hemorrhage | “0 (0.0)” | “0 (0.0)” | “3 (37.5)” | “1 (20.0)” | “4 (23.5)” |
| Neovascular AMD | “1 (33.3)” | “0 (0.0)” | “3 (37.5)” | “0 (0.0)” | “4 (23.5)” |
| Retinal exudate | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “3 (60.0)” | “3 (17.6)” |

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.5-2"></a>

###### Ocular safety

> “No dose-limiting toxicity was observed in this study.”
> “No patients experienced an ocular SAE or TEAE leading to discontinuation or death.”
> “There were no vitreous floaters, endophthalmitis, retinal detachment, insert migration into the anterior chamber, retinal vasculitis, posterior or anterior segment inflammation, vascular occlusive events, or ischemic optic neuropathy observed throughout the study.”
> “One patient with reduced BCVA had 3 separate reductions of 17, 18, and 16 letters, and another had a single drop of 25 letters.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.4.8.5-3"></a>

###### Systemic safety

> “Forty systemic, nonocular AEs were reported among 14 patients (82.4%).”
> “One nonocular TEAE, an increased laboratory value of γ-glutamyltransferase arising on day 58, was considered possibly treatment-related and mild.”
> “Two patients (11.8%) had SAEs during the study, including pneumonia in 1 patient and diverticulitis in the other, the latter resulting in death. In both patients, these SAEs occurred >6 months after receiving EYP-1901 at a time point when the study drug was undetectable in plasma.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

DAVIO enrolled 17 participants across 4 dose cohorts (1 to 8 participants per cohort) at 11 sites in the United States, without a control arm or masking, and no formal sample size calculation was performed. Four participants in the planned 3090-μg cohort received fewer inserts than planned because of injector difficulties and were reassigned to lower-dose cohorts. Efficacy and treatment-burden analyses were descriptive, excluded 1 participant who withdrew after week 16, and were added post hoc, with pre-enrollment treatment burden normalized from historical records. The authors state that unmasked investigators may have been biased in deciding on supplemental injections. The eligibility criteria (3 or more prior injections of the same agent in 6 months, dosing 7 to 10 days after the last anti-VEGF injection) limit applicability to treatment-naive participants, and the doses tested differ from the 2.7-mg phase 3 dose. The publication was sponsored by EyePoint, and 2 authors were EyePoint employees.

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/); [Thomas et al. (2026)](https://eyepoint.bio/wp-content/uploads/2026/05/ARVO-2026_DAVIO-2-Vision-Outcomes_Thomas_27Apr2026_FINAL.pdf)

<a id="topic-3.1.4.9-2"></a>

###### Limitations stated by the authors

> “Additionally, the study lacked a control group, meaning there was no comparison of the study drug with an existing therapy. Investigators were not masked to study enrollment, which may have biased their decision to administer supplemental injections during the study period. The study was not powered to make statistical comparisons.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.5"></a>

#### 3.1.5 APEX

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Study purpose: oral vorolanib (X-82) with as-needed anti-VEGF injections

> “The safety and efficacy of X-82, an orally administered inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor, was investigated for treatment of wet age-related macular degeneration (AMD) in a phase II clinical trial.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.1-2"></a>

###### Relationship of X-82 to EYP-1901

> “An oral formulation of vorolanib was previously studied in the phase II APEX Trial in patients with wAMD, which suggested its efficacy in wAMD.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Sites and registry dates

> “This study was conducted at 39 sites in the United States. There were 36 sites that screened subjects and 3 sites that did not screen any subjects.”

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2015-03-16” |
| Primary completion (actual) | “2017-12-12” |

Source: [ClinicalTrials.gov NCT02348359](https://clinicaltrials.gov/study/NCT02348359)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized, placebo-controlled dose-finding design

> “This phase II, randomised, double-masked, placebo-controlled trial enrolled subjects with a prior diagnosis of exudative AMD having received at least two intravitreal injections of anti-VEGF therapy.”
> “At each 4-week interval visit for 52 weeks, subjects were to be assessed to determine if rescue treatment was needed with anti-VEGF therapy.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.3-2"></a>

###### Early termination

> “Interim analysis found study had achieved primary objective”

Source: [ClinicalTrials.gov NCT02348359](https://clinicaltrials.gov/study/NCT02348359)

> “Due to gastrointestinal and hepatobiliary adverse events and the fulfilment of the primary endpoint, the trial was stopped prematurely after a second interim analysis.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.3-3"></a>

###### Interim analyses and the Data Safety Monitoring Committee recommendation to terminate

> “Based on a planned, unbiased, interim analysis conducted, once 90% of all subjects had reached their week 36 visit, it was concluded that the study had already achieved its primary endpoint of demonstrating non-inferiority in visual acuity of those on X-82 when compared with placebo.”
> “However, due to the relatively frequent occurrence of liver enzyme elevations, about 20% of the patients treated with X-82, and the number of patients discontinuing therapy due to AEs, ranging from 20% to 36% in the X-82 treated patients, the Data Safety Monitoring Committee recommended to the sponsor to terminate the trial due to an insufficient benefit to risk profile.”
> “The sponsor agreed with the recommendations, and all patients were subsequently discontinued from the study. A total of 28 (37%) of enrolled subjects were discontinued due to study termination.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.3-4"></a>

###### Masking, trial duration, and monthly assessments

> “Participants, physicians and care providers were all blinded to treatment arms.”
> “The duration of the trial was planned for 56 weeks with 52 weeks of treatment followed by 1 month off treatment.”
> “At each monthly visit, ETDRS BCVA assessment, ophthalmic examination, SD-OCT imaging, laboratory assessment, urinalysis, vital signs and an ECG were completed.”
> “Eligible patients showing a response to intravitreal anti-VEGF therapy and fulfilling all other study criteria returned on Day 1 to be randomised to a study treatment group and to receive another intravitreal anti-VEGF treatment.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Key inclusion criteria

> “Must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-VEGF injection at Screening Visit 1”

Source: [ClinicalTrials.gov NCT02348359](https://clinicaltrials.gov/study/NCT02348359)

<a id="topic-3.1.5.4-2"></a>

###### Prior treatment requirement and key exclusion criteria

> “Prior to enrolment, subjects were required to have received injections at intervals of 8 weeks or less and to have consistent macular fluid that was responsive to anti-VEGF therapy.”
> “pars plana vitrectomy within 30 days, the presence of proliferative diabetic retinopathy, prior glaucoma surgery and/or any other underlying diseases potentially limiting best-corrected visual acuity (BCVA) were excluded”
> “a history of a cerebral vascular accident, transient ischemic attack, significant cardiac disease or evidence of active gastrointestinal disease were excluded.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Treatment groups

> “Subjects were randomised equally into four groups that received either daily 50mg, 100mg or 200mg dosages of X-82 or a placebo tablet.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.5-2"></a>

###### Permitted as-needed anti-VEGF agents and duration of oral dosing

> “Daily dosing was continued for 52 weeks followed by a 4-week observation period.”
> “Bevacizumab, ranibizumab and aflibercept were all allowed, based on investigator preference, but the drug had to remain unchanged from what the patient received prior to study enrolment and the drug remained the same for the duration of the trial.”
> “These agents remained unchanged to eliminate the potential for any unwanted effect in our study results that could be attributed to a switch in an anti-VEGF agent.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.5-3"></a>

###### Criteria for as-needed anti-VEGF retreatment

> “Patients received anti-VEGF therapy at the screening visit and returned within 14 days to document an adequate anatomic response to anti-VEGF therapy.”
> “As-needed treatment with anti-VEGF was permitted if there was any increase in macular fluid/thickness compared with SD-OCT at screening visit 2 or if there was new or increased macular hemorrhage secondary to nAMD.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Visual Acuity Noninferiority to Placebo as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Registered primary outcome

> “The primary outcome is the change in the visual acuity score from Day -1 to 52 weeks after randomization.”

Source: [ClinicalTrials.gov NCT02348359](https://clinicaltrials.gov/study/NCT02348359)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Randomized and analyzed participants

> “A total of 157 subjects were randomly assigned and treated in the study.”

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

> “Approximately 132 subjects will be randomized into one of the four arms (33 subjects per dose group).”

Source: [ClinicalTrials.gov NCT02348359](https://clinicaltrials.gov/study/NCT02348359)

<a id="topic-3.1.5.7.1-2"></a>

###### Intention-to-treat and per-protocol participants with week 52 data

> “Overall, the ITT population started with a mean visual acuity of 71.0 (n=157; Snellen 20/40) and ended with a mean of 72.3 (n=81; Snellen 20/40) at week 52.”
> “Overall, the PP population started with a mean ETDRS BCVA score of 71.7 letters (n=92; Snellen 20/40) and ended with a mean of 71.2 letters (n=68; Snellen 20/40) at week 52.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Primary outcome population

> “Analysis restricted to subjects who completed 52 weeks of treatment”

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

<a id="topic-3.1.5.7.2-2"></a>

###### Intention-to-treat and per-protocol analysis sets and major protocol deviations

> “The ITT analysis included every patient that was randomised into the clinical trial. The PP population consisted of all ITT subjects without any major violation deviation of the protocol.”
> “The analyses of primary and secondary efficacy outcomes were performed on the PP population as a sensitivity analysis.”
> “Of those involved in ITT population analysis, 65% (102/157) were able to avoid major protocol deviations in dosing (defined as missing ≥15% of planned X-82 doses for the entire study)”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Disposition by treatment group

| Milestone | X-82 50 mg | X-82 100 mg | X-82 200 mg | Placebo |
| --- | --- | --- | --- | --- |
| Started | “40” | “39” | “39” | “39” |
| Completed | “29” | “22” | “25” | “27” |
| Not completed | “11” | “17” | “14” | “12” |

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

<a id="topic-3.1.5.8.1-2"></a>

###### Reasons for premature discontinuation of study treatment

> “Seventy-five (47.8%) subjects had study treatment prematurely discontinued for the following reasons: study termination (28 (37.3%) subjects), AE (27 (36.0%) subjects), withdrawal of consent (8 (10.7%) subjects), ‘other’ (5 (6.7%) subjects), SAEs (4 (5.3%) subjects), protocol deviation (1 (1.3%) subject), death (1 (1.3%) subject) and investigator decision (1 (1.3%) subject).”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Age and baseline visual acuity by treatment group

| Characteristic | X-82 50 mg, 40 participants | X-82 100 mg, 39 participants | X-82 200 mg, 39 participants | Placebo, 39 participants |
| --- | --- | --- | --- | --- |
| Age, mean, years | “75.7” | “73.5” | “75.0” | “75.9” |
| Best corrected visual acuity, mean, letters | “72.3” | “71.2” | “71.9” | “68.8” |

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Primary endpoint and anti-VEGF injection counts

> “The primary endpoint of non-inferiority of visual acuity compared with placebo was demonstrated in all groups receiving X-82 (p<0.001).”
> “There was a dose-dependent trend in the number of injections over a 52-week period, with the 50 mg (n=40), 100 mg (n=39), 200 mg (n=39) and placebo (n=39) group requiring 6.7, 6.0, 4.7 and 8.1 injections, respectively.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.8.3-2"></a>

###### Registry primary outcome: completers at week 52

| Group | Participants analyzed | Mean (SD) change in visual acuity, letters |
| --- | --- | --- |
| X-82 50 mg | “23” | “0.2(4.14)” |
| X-82 100 mg | “19” | “-0.9(6.57)” |
| X-82 200 mg | “17” | “1.7(5.58)” |
| Placebo | “22” | “-0.3(10.63)” |

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

<a id="topic-3.1.5.8.3-3"></a>

###### Noninferiority estimates by dose and proportion losing fewer than 15 letters

> “demonstrated a non-inferiority of visual acuity at the week 52 visit in all groups receiving X-82 when compared with placebo (−4.02 letters in the 50 mg group (p<0.000001), −1.71 letters in the 100 mg group (p<0.000001) and −2.33 letters in the 200 mg group (p<0.000001)).”
> “The negative estimates indicate less loss (or better maintenance) of visual acuity compared with placebo.”
> “Those in the 50 mg, 100 mg, 200 mg and placebo groups had a mean change from baseline in visual acuity of −0.4, −0.9, 0.3 and −0.5 letters at Week 52, respectively.”
> “Overall, 95.6% (87/91) of all patients lost fewer than 15 ETDRS letters by week 52.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.8.3-4"></a>

###### Participants requiring no further anti-VEGF injection and median time to first injection

> “Interestingly, there were several instances in which patients did not require another anti-VEGF injection after the final screening treatment was completed.”
> “This was more common in those receiving X-82 (7.5% (3/40), 10.3% (4/39) and 20.5% (8/39) in the 50 mg, 100 mg and 200 mg groups, respectively) than those receiving placebo (2.6% (1/39)) but was not statistically analysed and also does not take into account follow-up time.”
> “The median time to first anti-VEGF injection was 4.3 weeks for placebo-treated patients and 7.9, 8.1 and 8.4 weeks for patients administered 50 mg, 100 mg or 200 mg of X-82, respectively”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.8.3-5"></a>

###### Per-protocol anti-VEGF injection counts by dose

> “In the per-protocol group, an average of 6.3 injections were required per year.”
> “Looking at the individual groups, there was a dose-dependent trend to less as-needed anti-VEGF injections in patients receiving X-82 compared with sham: 6.4 injections in the 50-mg group, 5.1 injections in the 100-mg group, 4.8 injections in the 200-mg group, and 8.1 injections in the sham group.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-3.1.5.8.3-6"></a>

###### Subretinal fluid on optical coherence tomography at screening and week 52

> “In the placebo group, 56.4% (22/39) of patients were noted to have subretinal fluid on SD-OCT during the screening visit 2, while 81.8% (18/22) had presence of subretinal fluid at 52 weeks.”
> “In contrast, at the screening visit 2, 60% (24/40) of the 50 mg group, 51.3% (20/39) of the 100 mg group and 56.4% (22/39) of the 200 mg group had subretinal fluid on SD-OCT, while 78.3% (18/23), 52.6% (10/19) and 41.2% (7/17) of the 50 mg, 100 mg and 200 mg groups, respectively, had subretinal fluid on imaging on the week 52 follow-up.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.8.3-7"></a>

###### Fellow eye conversion to exudative AMD by 52 weeks

> “In the placebo group, 12.5% (3/24) of subjects with unilateral disease at baseline developed exudative AMD in their fellow eyes by 52 weeks, compared with 3.8% (1/26), 0% (0/27) and 0% (0/23) in the 50 mg, 100 mg, and 200 mg X-82 groups, respectively.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Authors' benefit-risk conclusion

> “Given the limited tolerability and safety issues observed, X-82 does not have a sufficient benefit to risk profile in treatment of patients with AMD.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.8.5-2"></a>

###### Selected adverse events with oral X-82

| Event | X-82 50 mg | X-82 100 mg | X-82 200 mg | Placebo |
| --- | --- | --- | --- | --- |
| Serious adverse events, total | “6/40 (15.00%)” | “7/39 (17.95%)” | “3/39 (7.69%)” | “2/39 (5.13%)” |
| Alanine aminotransferase increased | “8/40 (20.00%)” | “11/39 (28.21%)” | “9/39 (23.08%)” | “2/39 (5.13%)” |
| Diarrhoea | “1/40 (2.50%)” | “4/39 (10.26%)” | “9/39 (23.08%)” | “2/39 (5.13%)” |
| Dysgeusia | “3/40 (7.50%)” | “5/39 (12.82%)” | “10/39 (25.64%)” | “0/39 (0.00%)” |
| Hair color change | “2/40 (5.00%)” | “10/39 (25.64%)” | “13/39 (33.33%)” | “0/39 (0.00%)” |

Source: [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

<a id="topic-3.1.5.8.5-3"></a>

###### Discontinuation of oral vorolanib development in AMD

> “The APEX Trial was stopped prematurely due to gastrointestinal and hepatobiliary AEs associated with oral vorolanib use such as elevated liver enzymes, and due to the fulfillment of the primary endpoint (noninferiority to placebo).”
> “EYP-1901 was developed as a localized, intravitreal, sustained-delivery formulation of vorolanib in an attempt to reduce the injection burden of wAMD treatment and also reduce systemic adverse effects of vorolanib.”

Source: [Patel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11179418/)

<a id="topic-3.1.5.8.5-4"></a>

###### Treatment-emergent adverse events, severity, discontinuations, and death

> “Overall, 148 (94.3%) subjects experienced at least one treatment-emergent adverse event (TEAE) and 74 (47.1%) subjects experienced one treatment-related TEAE.”
> “A total of 16 (10.2%) subjects overall experienced at least one severe TEAE, with 4 (2.5%) of these subjects having a TEAE that was considered related to study treatment.”
> “In total, 39 (24.8%) subjects experienced at least one TEAE leading to permanent discontinuation of study treatment (8 (20.0%), 12 (30.8%), 15 (38.5%) and 4 (10.3%) subjects in the 50 mg, 100 mg, 200 mg and placebo groups, respectively).”
> “One (2.6%) subject died during the study (sudden cardiac death) during treatment with X-82 (100 mg), which was not considered related to study treatment.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="topic-3.1.5.8.5-5"></a>

###### Early termination for sustained hepatic abnormalities by dose

> “In several instances, these elevations resolved without any intervention; however, 5.0% (2/40), 15.4% (6/39) and 17.9% (7/39) in the 50 mg, 100 mg and 200 mg groups, respectively, required early termination of the trial secondary to sustained hepatic abnormalities.”
> “No patients from the placebo group required early termination for liver enzyme elevations.”

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

APEX evaluated daily oral vorolanib (X-82) at 50, 100, and 200 mg, not the intravitreal insert, so its efficacy results do not transfer directly to EYP-1901; its relevance to this report is the systemic adverse event profile of vorolanib at oral exposures. The trial randomized 157 participants and was stopped early after a second interim analysis, with 103 of 157 participants (65.6%) completing the study. The registry primary outcome analysis was restricted to participants who completed 52 weeks of treatment. The comparator was placebo plus as-needed anti-VEGF injections rather than a fixed-interval anti-VEGF regimen. Statements here are drawn from the full publication and the registry record.

Source: [Cohen et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32586932/); [ClinicalTrials.gov NCT02348359 results](https://clinicaltrials.gov/study/NCT02348359?tab=results)

<a id="heading-3.1.6"></a>

#### 3.1.6 X82-OPH-102

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Primary objective

> “To undertake safety testing of oral X-82 administered for the treatment of neovascular AMD.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Sites and study period

> “Subjects with wet age related macular degeneration were enrolled at 5 US retinal clinics between November 2012 and March 2015”

Source: [ClinicalTrials.gov NCT01674569 results](https://clinicaltrials.gov/study/NCT01674569?tab=results)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Open-label dose escalation

> “Phase 1, open-label, uncontrolled, dose-escalation study at 5 US retinal clinics between November 2012 and March 2015”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.3-2"></a>

###### Dose escalation rules, dose-limiting toxicity definition, and maximum tolerated dose

> “The dose escalated from one level to the next in the absence of any DLT.”
> “Dose-limiting toxicity was defined as a drug-related safety event during the first 2 weeks of treatment that was severe enough to require removal of the participant from the study.”
> “The maximum tolerated dose was the maximum dose at which no DLT occurred in a group of 3 participants or no more than 1 DLT in a group of 6.”
> “Participants attended for screening, day 14, and then monthly for 7 months (210 days).”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Key inclusion criteria

> “No previous treatment with anti-VEGF therapy or prior anti-VEGF therapy with evidence of response to treatment and the need for additional treatment.”
> “Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA 20/32 to 20/320 in the study eye(s).”

Source: [ClinicalTrials.gov NCT01674569](https://clinicaltrials.gov/study/NCT01674569)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Oral X-82 dose cohorts

> “Participants received oral X-82 for 24 weeks at 50 mg alternate days (n = 3), 50 mg daily (n = 8), 100 mg alternate days (n = 4), 100 mg daily (n = 10), 200 mg daily (n = 7), and 300 mg daily (n = 3), with intravitreous anti-VEGF therapy using predefined retreatment criteria.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.5-2"></a>

###### Criteria for anti-VEGF rescue therapy and choice of agent

> “Rescue anti-VEGF therapy was permitted if predefined criteria were met, including any increase in macular fluid or thickness on SD-OCT compared to baseline, new or increased SRF or IRF, enlargement or new PED, or new or worsening macular hemorrhage.”
> “Rescue agents were matched to each patient’s prior treatment regimen.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Main outcome measures

> “The main outcome was adverse events. Other outcomes included visual acuity, central subfield retinal thickness, and number of anti-VEGF injections.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Enrolled and completing participants

> “Thirty-five participants with neovascular age-related macular degeneration, 7 of whom were treatment naive.”
> “Of 25 participants (71%) who completed the 24 weeks of X-82 treatment, all except 1 maintained or improved their visual acuity (mean [SD], +3.8 [9.6] letters).”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Efficacy analysis restricted to completers

> “The mean and standard deviation was calculated for all subjects who completed 6 months of treatment with oral X82”

Source: [ClinicalTrials.gov NCT01674569 results](https://clinicaltrials.gov/study/NCT01674569?tab=results)

<a id="topic-3.1.6.7.2-2"></a>

###### Statistical approach and efficacy population

> “No formal hypothesis testing was performed.”
> “The efficacy population comprised all those who completed the course of X-82 treatment.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Withdrawals

> “Ten participants withdrew consent or discontinued prematurely, 6 owing to adverse events attributed to X-82 including leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and nausea/anorexia (n = 1).”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.8.1-2"></a>

###### Completion at 3 and 6 months and discontinuations by dose group

> “Twenty-eight participants completed 3 months, and 25 completed 6 months.”
> “Of 35 participants, 25 completed 24 weeks of treatment. Six discontinued X-82 owing to AEs potentially related to X-82 (2 in the 50 mg daily group, 1 each in the 100 mg daily and 200 mg groups, and 2 in the 300 mg group). Four discontinued owing to unrelated events”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Demographics

> “Of the 35 participants, the mean age was 76.8 years, 16 were men and 19 were women, and 33 were white and 2 were nonwhite.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Visual acuity, retinal thickness, and anti-VEGF injections among completers

> “Fifteen participants (60%) required no anti-VEGF injections (mean, 0.68).”
> “Mean [SD] central subfield thickness reduced by −50 [97] μm, with 8 participants (all receiving at least 100 mg daily) demonstrating sustained reductions despite no anti-VEGF injections.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.8.3-2"></a>

###### Anti-VEGF rescue injections among completers and pre-enrollment injection rate

> “The mean number of anti-VEGF injections in the 25 participants who completed 24 weeks of treatment was 0.68 (median, 0; range, 0-4; interquartile range, 0-1), with 15 (60%) not requiring any anti-VEGF rescue injections.”
> “The mean time to the first rescue injection was 130 days in the 10 participants who completed the study and required an injection.”
> “None of those assigned to 300 mg daily required intravitreous injections while receiving X-82.”
> “Previously treated participants who completed 24 weeks of X-82 treatment had a mean (SD) of 9.0 (4.1) injections yearly prior to enrollment.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.8.3-3"></a>

###### Visual acuity change across all participants and by dosing frequency

> “Mean BCVA change across all 35 patients was +3.5 (9.7) letters.”
> “A gain of +4.3 (9.2) letters was seen in the 28 patients who were dosed at least daily.”
> “In 3 patients (8.6%) dosed with 100 mg on alternate days, 200 mg daily, and 300 mg daily, an at least 5-letter worsening was seen.”

Source: [Dhoot (2025)](https://pubmed.ncbi.nlm.nih.gov/40505850/)

<a id="topic-3.1.6.8.3-4"></a>

###### Central subfield thickness response at higher doses and fellow eye outcomes

> “Five of 7 participants receiving 200 mg had a reduction in thickness, as did 2 of 3 receiving 300 mg.”
> “No participants developed new neovascular AMD in the fellow eye, but 1 (receiving 50 mg daily) developed new exudation from a previously treated fellow eye CNV.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Adverse events attributed to oral X-82

> “The most common adverse events attributed to X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevation (n = 4). A dose relationship to the transaminase elevations was not identified; all normalized when X-82 was discontinued.”
> “X-82 can be associated with reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsuited to treatment.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.8.5-2"></a>

###### Registry adverse event totals

| Category | All participants |
| --- | --- |
| Serious adverse events | “3/35 (8.57%)” |
| Other adverse events | “28/35 (80.00%)” |
| Diarrhoea | “5/35 (14.29%)” |

Source: [ClinicalTrials.gov NCT01674569 results](https://clinicaltrials.gov/study/NCT01674569?tab=results)

<a id="topic-3.1.6.8.5-3"></a>

###### Ocular adverse events, severe events, and serious adverse events

> “There were 4 ocular AEs in 4 of 35 participants (11.4%)”
> “Three AEs (8.6%) were considered severe: 1 case of multiple myeloma, 1 of pulmonary hypertension, and 1 with an isolated, 5-fold increase in serum transaminase, which was reversible and not associated with other abnormalities (hence, not considered an SAE).”
> “Of 94 systemic AEs, 32 were considered related to X-82”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.8.5-4"></a>

###### Incidence of liver enzyme elevation and gastrointestinal symptoms

> “Liver enzyme elevations were reported as AEs 10 times across 5 participants.”
> “The main downside of treatment was elevated liver enzymes and gastrointestinal symptoms, which occurred in 11% and 14% of participants, respectively.”
> “Of 35 participants, 6 (17%) did not tolerate X-82, and an additional 4 failed to complete the study.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

X82-OPH-102 evaluated oral vorolanib (X-82), not the intravitreal insert, in 35 participants across 6 dose cohorts of 3 to 10 participants, without a control arm or masking. Efficacy outcomes were reported only for the 25 participants (71%) who completed 24 weeks, and 6 participants (17%) discontinued because of adverse events attributed to X-82, so the efficacy estimates are subject to attrition bias. Its relevance to this report is the systemic adverse event profile of vorolanib at oral exposures, including transaminase elevations. The study was funded by Tyrogenex, and 3 authors were Tyrogenex employees.

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

<a id="topic-3.1.6.9-2"></a>

###### Author-stated limitations

> “The main weaknesses, inherent to most open-label phase 1 studies, are a small sample size and lack of both masking and a control group.”
> “This study cannot determine the level of patient compliance with X-82 in a clinical setting.”
> “Because 80% of the participants were already receiving anti-VEGF therapy at enrollment, this may reduce the potential for clinical improvement.”

Source: [Jackson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710207/)

## Related pages
- [Duravyu (vorolanib intravitreal insert): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Duravyu (vorolanib intravitreal insert): Wet age-related macular degeneration](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/executive-summary.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economics.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: References](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/references.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/prevalence.md)
- [Duravyu (vorolanib intravitreal insert) in Wet age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/cost-effectiveness-analyses.md)
